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SUMMARY.
The history of drug therapy, from the earliest herbal remedies to 
the impressive range of drugs available today, has proved the accuracy 
of the observation made by Sir William Osier in 1891 that "a desire to 
take medicine is, perhaps, the great feature which distinguishes man 
from other animals”. Modem therapeutics has brought undoubted benefit 
to the patient, but not without risk. Unwanted effects and adverse 
reactions have now become an integral part of drug therapy. A small 
but significant proportion of these adverse reactions can be attributed 
to drug interactions, the phenomenon which occurs when the effects of 
one drug are modified by the prior or concurrent administration of 
another. Drugs may interact in ways not readily foreseeable from the 
action of either agent alone and may result in increased or reduced 
therapeutic efficacy, or sometimes toxic or even fatal reactions.
Numerous surveys have proved that in hospital medicine, multiple 
drug therapy is now common practice and such interactions as have come 
to light are merely a small indication of an ever increasing problem.
Ihe number of over-the-counter drugs which can be purchased 
indiscriminately by the public complicates matters further because of 
the difficulty in ascertaining their composition and strength, the 
dosages employed, and the combinations in which they are taken with 
prescribed drugs. Alcohol consumption also adds to the therapeutic 
problems which face the doctor. If safe and effective therapy is to be 
attained, he must be aware of all the drugs that a patient is taking and 
carefully review all drug combinations.
Other factors may play an important part in determining the overall 
response of a patient to a drug, and drug interactions must be seen in 
this perspective. Genetic, environmental and pathophysiological factors, 
particularly renal and hepatic disease, together with allergy and 
idiosyncrasy may all make important contributions to this response.
(xvii)
In addition, variations in the biological availability of drugs due to 
pharmaceutical factors may assume importance. Assessment of the 
contribution of these various factors in individual patients is 
necessary for rational prescribing. Renal impairment, for example, 
reduces the clearance of drugs such as digoxin which depend on 
glomerular filtration for their excretion. Pharmacokinetic studies 
can derive mathematical models which define these changes accurately and 
predict appropriate dosage adjustments to maintain optimum therapeutic 
effect. Simulation of the changes can be usefully achieved by analogue 
computation.
A number of basic mechanisms are responsible for many drug 
interactions and an appreciation of these mechanisms can greatly 
facilitate their interpretation, prevention and treatment. Interactions 
can be viewed in terms of the three phases of drug action, the 
pharmaceutical phase, the pharmacokinetic phase and the pharmacodynamic 
phase. Quantitative changes, reflected as alterations in plasma and 
tissue concentrations, occur during pharmaceutical and pharmacokinetic 
interactions while qualitative changes at receptor sites modifying onset, 
intensity or duration of action, or interference with, homeostatic 
mechanisms occur as a result of interactions in the pharmacodynamic phase.
It is virtually impossible for the practising doctor to sustain the 
mass of detailed information which is now available on drug interactions. 
To overcome this problem, a simple, portable drug interaction warning 
system, the Drug Disc, has been developed. It consists of a reversible 
unit of two concentric superimposed discs which pivot freely about their 
common centre. Interactions are indicated by symbols which appear in a 
window cut into the upper disc when individual drugs or drug categories 
shown on the two discs are brought into alignment. The information 
presented embraces the majority of drug interactions which have a bearing 
on therapeutics and different symbols are used to grade interactions
(xviii)
according to their degree of clinical significance. This grading 
was based on the nature and severity of the interaction, the adequacy 
of published information, and opinions expressed by the developers of 
the Disc, including a Working Party established by the Scottish Home and 
Health Department, and 450 doctors and pharmacists who participated in 
a trial of the Disc in the United Kingdom. This survey of attitudes 
about the warning system indicated that the majority of participants 
found the information provided to be both clinically useful and 
informative. Subsequent consumer research in other countries has 
confirmed that the system would be of value both as a practical aid in 
prescribing and in teaching. The degree of interest and enthusiasm 
stimulated by the Drug Disc showed that drug interactions are an aspect 
of modem medicine that cannot be ignored, and suggested that this kind 
of aid to prescribing was warranted. It is planned to effect a free 
distribution of the Disc to Health Service Doctors in the United Kingdom 
and the Excerpta Medica Foundation has accepted responsibility for its 
worldwide distribution.
Further experience with drug combinations and the introduction of 
new drugs will largely dictate much of the relevance of drug interactions 
in the future. The Drug Disc will be subjected to constant review and 
appropriate changes made whenever necessary. It is hoped that a system 
of this kind will foster a more critical approach to multiple drug therapy 
and help to reduce many of the hazards implicit in drug combinations.
C H A P T E R  I
I N T R O D U C T I O N
INTRODUCTION
Combinations of drugs have characterised the practice of medicine 
in its many forms throughout the ages. Herbal remedies and various 
concoctions of vegetable or animal material contained mixtures of 
chemicals, but they were usually administered empirically and little 
attempt was made to identify individual ingredients. The fact that 
they might provide a ncurelf was sufficient in itself. Modem 
analytical and synthetic techniques have produced therapeutic agents 
which have, to a large extent, replaced both the former therapeutic 
empiricism and the dependence on Mother Nature. A doctor can now 
choose to use powerful, specific drugs in the treatment of a patient 
and his knowledge and understanding of drugs and disease should give 
him complete control over the therapeutic substances he prescribes.
Even now, however, it is rare for patients to receive only one 
drug at a time. Many surveys of the use of drugs, particularly in 
the hospital environment, highlight the popularity of multiple drug 
therapy. There is also little doubt that outside hospital, 
polypharmacy is even more widespread. In this setting, patients 
have ready access to over-the-counter medicinal products, but little 
awareness of their inherent dangers. Modem marketing and advertising 
have given great incentive and encouragement to self-medication but 
have failed to stress its main drawback - that any purely symptomatic 
benefit may be gained at the expense of a carefully prescribed 
therapeutic regimen.
There is now no doubt that the simultaneous exhibition of 
several drugs may complicate therapy by presenting the possibility of 
drug interactions. This implies that a combination of drugs alters 
the efficacy or toxicity of one or more of the drugs. The proliferation 
of drug therapy and the introduction of new and more potent drugs will 
only serve to aggravate this problem -unless it can be brought to the
2attention of all prescribing doctors. Although there are many 
excellent reviews of drug interactions, the subject nevertheless 
presents a complex and profound problem and the practising doctor 
would find it virtually impossible to sustain the mass of detailed 
information now available. Be should certainly be aware, however, 
of the potential for interactions and have an appreciation of their 
clinical significance.
The availability of so many potent drugs, the common practice 
of polypharmacy and the widespread unmonitored self-medication with 
over-the-counter products presents drug interactions as an aspect of 
modem medicine that cannot be ignored. To assist the practitioner 
in the identification and prevention of clinically significant drug 
interactions, relevant information should be immediately available 
in as concise a form as possible, A drug interaction warning system 
has been conceived and developed to provide this.
C H A P T E R  2
BACKGROUND TO DRUG INTERACTIONS
2. BACKGROUND TO DRUG INTERACTIONS
2.1 HISTORICAL PERSPECTIVE
Disease expresses itself as fear, anxiety and pain, and 
throughout history man has sought to find relief by searching for 
effective remedies. Indeed, in 1891, in an address to the Johns 
Hopkins University entitled “Recent Advances in Medicine”, Sir 
William Osier said
”A desire to take medicine is, perhaps, 
the great feature which distinguishes 
man from other animals”.
It is fairly certain, however, that until the late 19th Century, 
most therapeutic regimens were ineffective because they consisted 
of many agents which were, pharmacologically, virtually inert.
Despite this, drugs were traditionally prescribed in mixtures, and 
there is no doubt that the use of many drugs in the treatment of a 
single disease or symptom complex had a definite psychological appeal, 
both to the patient and to the doctor. William Withering’s approach 
to the problem of “dropsy”, published in 1785, typified this attitude 
when he advocated treatment which included "medicines of the 
deobstruent, tonic, antispasmodic, diuretic and evacuate kinds”. 
Unfortunately, recent surveys of drug usage throughout the world have 
all testified to the continuing appeal of multiple drug therapy, a 
practice presumably based on the fallacious premise that ^ore" is 
necessarily better than “less”.
Drugs, however, are no longer inert substances. While there is 
no dispute about their tremendous benefits, unwanted effects and 
adverse reactions are now an integral part of drug therapy and 
constitute part of the price paid for more effective remedies. Adverse
4reactions are inevitable when modem therapeutics demands that drugs 
modify, stimulate or suppress biological processes. Today, the 
concept of a "completely safe drug" is unreal, but if sensible 
precautions are taken, the risks of modem drugs can be minimised. 
Their abuse, however, by both the public and by doctors can only 
bring them into unwarranted disrepute.
Multiple drug therapy, whether it has been prescribed or self­
administered, is one such area of abuse which cannot be explained on 
the basis of the action of a single drug, but is due to two or more 
drugs acting simultaneously. Adverse reactions resulting from 
multiple drug therapy make up only a small proportion of all adverse 
drug reactions, but account for a disproportionate number of deaths, 
and the problem of adverse drug interactions has received increasing 
attention over the past decade.
2.2. HOSPITAL PRESCRIBING AND DRUG MONITORING
2.2.1. Multiple drug therapy in hospital -practice
Today, the average hospital patient is treated with at least 
five drugs simultaneously, this figure varying somewhat in different 
parts of the world. One of the first comprehensive surveys of drug 
usage in hospital practice was carried out by Smith, Seidl and Cluff 
(1966). They studied 900 consecutive patients on a 33-bed 
semi-private medical ward in Baltimore, and reported that 37$ of their 
patients received 0-5 drugs during one hospital admission, 42$ 
received 6-10 drugs, 14$ 11-15 drugs, 4$ 16-20 drugs and 2$ 21 drugs 
or more. They commented on the impressive relationship between the 
rate of adverse reactions and the number of drugs administered#
5This was the first time that a definite relationship was established 
between untoward effects and multiple drug therapy# Previously, 
emphasis had been laid on the toxic effects attributable to individual 
drugs. Patients given 12 or more drugs were particularly susceptible 
to adverse reactions, and this suggested that the relationship of rate 
of reactions to number of different drugs was not simply additive, but 
more complex and compounded of other factors. Unexpected 
pharmacological responses were occurring as a result of drug 
combinations which could therefore be regarded as drug interactions. 
These combinations included indomethacin and dextropropoxyphene, 
barbiturates and tranquillisers, tetracycline and mixtures of magnesium 
and aluminium hydroxide, and reserpine and guanethidine• These
observations extended previous reports of drug combinations found to 
be associated with altered and often adverse drug effects, including 
digitalis and mercurial diuretics (Lown, Marcus and Levine, 1959)» 
amphetamine and monoamine oxidase inhibitors (Bay, 1962), phenobarbitone 
and dicoumarol (Cucinell, Conney and Sansur, 1965) and sulphonamide and 
tolbutamide (Christensen, Hansen and Kristensen, 1963).
More recent studies of drug use during hospitalisation have 
reaffirmed the medical profession's determination to persist in multiple 
drug therapy. In a Pinnish survey of 1000 consecutive patients in two 
medical wards, Sotaniemi and Palva (1972) reported that about 70$ of 
the patients received 1-4 drugs regularly, and 21$ received 5 or more. 
Dollery (1973) reported that the average number of drugs per patient 
stay in a London Hospital was 6, and the maximum 21*
2.2.2. International drug surveillance
The Boston Collaborative Drug Surveillance Program (jick et al, 1970)
reported an average of 8.4 drug exposures per patient, with a range of 
5.5 to 10.0. In an editorial on Adverse Drug Interactions (Boston 
Collaborative Drug Surveillance Program, 1972) analysis of data on 
9,900 monitored patients indicated that there had been 83,200 drug 
exposures and 3»600 reported adverse reactions. Two hundred and 
thirty four (or 6.9$) of the adverse reactions were attributed to drug 
interactions. Cumulative pharmacological effects seemed to account 
for most interaction problems with emphasis being laid on central 
nervous system depression resulting from the administration of two 
or more central nervous system depressant drugs. hypotension, 
gastrointestinal bleeding, psychotic behaviour and bowel superinfection 
were also reported complications of combined drug therapy.
In 1969 the Boston Collaborative Drug Surveillance Program began 
to extend its field of survey outwith North America by including 
hospitals in Israel, (Hadassah-Hebrew University Hospital, Jerusalem; 
Beilinson Hospital, Tel-Aviv and Asaf-Harafe Hospital, Tel-Aviv) and 
more recently, in New Zealand (Auckland Hospital) and Scotland (The 
Western Infirmary, Glasgow and Stobhill General Hospital, Glasgow).
The aim of the Glasgow Drug Surveillance Programme was to collect data 
from patients admitted to two University Medical Units - the University 
Department of Medicine at the Western Infirmary and the Department of 
Materia Medica at Stobhill General Hospital. The present author has, 
therefore, been fortunate in having an association with this Drug 
Surveillance Programme since monitoring started in the Department of 
Materia Medica in 1973.
The main aims of the programme were to:
1. Quantitate clinical drug use
2. Evaluate known or suspected adverse drug effects
3# Detect unsuspected adverse drug effects
4. Assess reports in the literature.
HJie quantitative analysis of clinical drug use in Glasgow and in 
other centres has revealed widely differing prescribing patterns 
throughout the world. A consistent finding has been that patients 
in North American hospitals receive more drugs during hospitalisation 
than do their counterparts in Europe, the Middle East or Australasia.
On average, medical inpatients in the United States received 9*1 drugs 
per admission as compared with 7«1 drugs for Canadian, 6.3 for Israeli,
5*8 for New Zealand and 4*6 for Scottish patients (Table l) (Lawson, 
Personal communication, 1974)•
These differences in prescribing habits merited further analysis 
and the countries with the highest (United States) and lowest (Scotland) 
drug use were compared. A large group of American (1442) and Scottish 
(721) patients in general medical wards were matched for age, sex, 
survival, primary discharge diagnosis, duration of hospitalisation and 
various clinical parameters such as blood pressure, renal function and 
haematological status.
The figures oh drug usage already quoted show that American 
patients received over twice as many drugs as did their Scottish 
counterparts, and American patients were much more likely to receive at 
least ten drugs. There is, therefore, little doubt that the Scottish 
practice reflected by these figures favours relative economy in the use 
of drugs.
Moir and Eedley (1971) reported similar findings when reviewing a 
method of prescribing and recording drugs in the Aberdeen General 
Hospitals Group, devised by Crooks et al (19^5 and 1967). The average 
number of drugs per patient per admission in the whole group including 
medical, surgical, gynaecological and orthopaedic wards, was 4*5*
Table 2 shows the twelve most commonly prescribed drugs in the 
United States and in the Glasgow hospitals, with per cent of patients 
exposed (Wallace and Lawson, personal communication, 1974) and illustrates
Country Drugs per admission
U.S.A. 9.1
Canada 7.1
Israel 6.3
New Zealand 5.8
Scotland 4*6
TABLE I International comparison of drug use
during hospitalisation from the Boston 
Collaborative Drug Surveillance Program 
(Lawson, personal communication, 1974)*
u. s. A. SCOTLAND(Glasgow)
Drug fo patients Drug $  patients
exposed exposed
Milk of magnesia 51 Nitrazepam 34
Chloral hydrate 45 Potassium
chloride 26
Potassium
chloride 35 FRUSEMIDE 21
Propoxyphene 32 AMPICILLXN 14
Dextrose 5fo 32 Diazepam 14
Aspirin 25 Sodium
chloride 12
DIGOXIN 23
Aluminium and Paracetamol 12
magnesium
hydroxides 21 DIGOXIN 12
Mul ti vi t amins 20 FERROUS SULPHATE 11
Diphenhydramine 19 Milpar 11
Pentobarbitone 18 Dihydrocodeine 10
Pethidine 18 CO-TRIMOXAZOLE 9
TABLE 2 International comparison of drug use in medical
patients showing the 12 commonest drugs prescribed, 
from the Boston Collaborative Drug Surveillance 
Program (Wallace and Lawson, personal communication,
1974).
the differences in physician attitudes to prescribing in the two 
countries. The greater enthusiasm with which American physicians 
prescribe non-specific, symptomatic treatment is obvious. Only one 
(digoxin) of the twelve most commonly prescribed drugs in the United 
States has specific therapeutic activity in contrast to five of the 
Scottish drugs (frusemide, ampicillin, digoxin, ferrous sulphate and 
co-trimoxazole)•
Although there is no way of assessing the relative benefits of 
the different patterns of drug usage in the United States and Scotland 
as reflected by these studies, it is certain that drug treatment in 
America, when compared with that in Scotland, costs the patient more, 
both in terms of financial outlay and adverse drug effects. Three 
hundred and seventy (26$) American patients experienced one or more 
adverse drug effects as compared with 107 (15$) of Scottish patients 
(p <0.001 )* The greater frequency of adverse reactions in American 
patients reflected the practice of multiple drug therapy rather than a 
greater prevalence of toxicity to individual drugs. This was in 
agreement with the general principle derived from previous findings 
that the incidence of adverse drug reactions was directly related to 
the number of drugs prescribed simultaneously (Seidl et al 1966; Smith 
et al 1966; Hoddinott et al 1967; Qgilvie and Ruedy 1967; Hurwitz 
1969)* Thus the increased reaction rate associated with multiple drug 
therapy may result from drug interactions and an exaggeration of the 
risks normally associated with drug therapy#
2.3. SELF MEDICATION
The data obtained so far by comprehensive drug monitoring has been 
solely concerned with the situation in hospital practice. Lasagna 
(I963-I964) speculated that the amount of trouble from drugs which was
9publicised represented only the "floating tip of an iceberg" with much 
of the difficulty remaining hidden beneath the surface of our awareness. 
Over the past decade, some of the difficulty with prescribed drugs has 
been uncovered by drug monitoring programmes, but Lasagna's comment 
still applies to the problem of self-medication with non-prescription 
drugs.
Concern with the incidence and source of adverse drug reactions in 
hospital patients has not been as vigorously expressed with regard to 
outpatients or patients seen in general or private practice. frequently 
the ambulatory patient requires greater supervision and surveillance as 
he usually exercises complete control over self-medication, and this can 
significantly influence the effectiveness of a prescribed therapeutic 
regime •
In 1965 > the Committee on Safety of Drugs stated that "the public 
should be made increasingly aware that no effective drug is entirely 
without hazard, even a drug which can be bought without a prescription, 
and doctors, for their part, should bear in mind that drug-induced 
illnesses may be the result of self-medication by the patient",.
2.3*1# Over-the-counter (o-t-c1 drugs.
Non-prescription or over-the-counter (o-t-c) drugs represent special 
problems to the doctor attempting to avoid therapeutic mishaps:
1# Hie composition and strength of o-t-c drugs 
are often vague or cannot be ascertained.
2* Hiey may contain potent pharmacological agents.
3. Hie same drug, in a somewhat higher dose, may be 
available only on prescription.
It may, therefore, be very difficult to predict the effect of self- 
medication on a given therapeutic regimen, and the patient employing an
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o-t-c drug without supervision may actually treat himself with doses 
which would normally only be prescribed, and which could give rise to 
untoward reactions. It is, therefore, incumbent on the doctor to be 
aware of all the drugs that a patient is taking if therapeutic mishaps, 
particularly adverse drug interactions, are to be avoided. It would 
also be sensible if the same sort of information could be made 
available to the pharmacist or retail chemist, even although this 
might encroach upon certain professional and ethical considerations.
A suitable treatment card issued to the patient by the general 
practitioner could be presented when necessary to the pharmacist.
Indeed Block and Lamy (1968), in reviewing the responsibility of the 
pharmacist to the patient, pointed out that the unsuspecting, 
unquestioning pharmacy customer is a hazard to himself and the 
pharmacist's maintenance of complete patient record cards, listing 
drug idiosyncrasies, allergies and current medication would better 
enable him to fulfil., his responsibility to the patient.
The monitoring of o-t-c drugs presents peculiar difficulties 
because reactions will only be reported by doctors if they are aware 
that the patient has been treating himself. The incidence of such 
reactions is rather more difficult to calculate than that of reactions 
to prescribed drugs, because estimates of consumption of the drugs 
involved are much less reliable, and very few studies of this have 
been undertaken. However, one study, conducted about 20 years ago, 
gave some insight into the size of the problem. Jefferys, Brotherston 
and Cartwright (i960) surveyed 1399 adults and 1056 children on a post­
war working class housing estate with particular reference to the kind 
of medicines consumed in a four week period. About a quarter of the 
sample had taken prescribed medicines in this period. The proportion 
of individuals who had taken or used some medicine which they had 
obtained without a prescription was very much higher - about two out
of every three individuals. The report was not concerned with adverse 
drug reactions or drug interactions, but it was interesting to note 
that the majority of those who took medicine prescribed by their 
general practitioner supplemented it with self-prescribed remedies.
In a much smaller study of 30 men recently discharged home from 
hospital, CLinite and Kabat (1969) reported that 83$ of subjects had 
resumed self-medication with non-prescription drugs as a supplement to 
their prescribed medication within one week of discharge. These 
observations would tend to reinforce the view expressed about the role 
and responsibility of the pharmacist in preventing unnecessary drug 
interactions.
Any accurate assessment of the number of o-t-c products now 
marketed is virtually impossible. Block and Lamy (19&9) referring to 
the American pharmaceutical market, quoted about 3000 manufacturers,
600 classifications and approximately 6000 products, which gave an 
indication of the vast number of preparations available. A recent 
personal survey by the present author of the o-t-c analgesic 
preparations available in a large city retail chemists revealed 70 
preparations, 27 containing aspirin, 26 containing paracetamol and 17 
others containing such drugs as codeine and salicylamide. Many aspirin 
and paracetamol preparations are combined with other drugs, for example 
barbiturates, antihistamines and sympathomimetic amines, (Tables 3 and 
4*) This serves to illustrate the "hidden" dangers of many e-t-c 
products, as seemingly innocuous drugs may contain potent pharmacological 
substances.
Table 5 shows the range of o-t-c drugs commonly available together 
with ingredients which may interact with prescribed drugs, and some 
examples of reported interactions are given in Table 6*
2.3.2. Alcohol
Drug(s) Proprietary Product
BUTOBARBITONE Sol-Tercin
CHLORPHENIRAMINE
PHENYLEPHRINE Capriton
DEXTROPROPOXYPHENE Dolasan, Napsalgesic
MEPROBAMATE Equaprin
METHOCARBRAMOL Robaxisal Forte
TABLE 3 Drugs combined with aspirin in single 
preparations.
Drug(s) Proprietary Product
BUTOBARBITONE
DEXTROPROPOXYPHENE
DICHLORALPHENAZONE
ORPHENABRINE
OXYPHENBUTAZONE
PHENYLBUTAZONE
PHENYLEPHRINE
MEPYRAMINE
PHENYLPROPANOLAMINE
PHENYLPROPANOLAMINE
MEPYRAMINE
PHENIRAMINE
PSEUDOEPHRINE
Dolalgin
Bistalgesic
Eldo-Sed
Norgesic
Tandalgesic
Parazolidin
Sinulin
Triogesic, Rinurel
Triotussic 
Paragesic
TABLE 4 Drugs combined with paracetamol in single 
preparations.
Category Interacting ingredient(s)
Analgesics Aspirin, salicylates.
Antacids Aluminium, calcium, magnesium, 
bicarbonate, citrate.
Cold cures Antihistamines, aspirin, 
belladonna alkaloids, 
sympathomimetic amines.
Cough syrups, elixirs and Alcohol, antihistamines,
expectorants ammonium chloride.
Diarrhoea remedies Kaolin, chalk and other
absorbents.
Laxatives Surfactants.
Travel sickness preparations Antihistamines, belladonna 
alkaloids.
Nasal spray and drops Sympathomimetic amines.
Tonics Alcohol, haematinics.
TABLE 5 Commonly available over-the-counter (o-t-c) drugs 
which may interact with prescribed drugs.
o-t-c drug Possible interaction with prescribed drugs.
Analgesics Haemorrhage with anticoagulants.
Antacids Decreased absorption, notably 
of tetracycline.
Cold cures Hypertensive crises with 
monoamine oxidase inhibitors.
Cough syrups, elixirs Excess central nervous system
and expectorants depression with sedatives 
and tranquillisers.
Diarrhoea remedies Decreased absorption, e.g. 
with digoxin.
Laxatives Alteration of rate and/or 
extent of absorption of a 
variety of drugs.
Travel sickness Excess central nervous system
preparations depression with sedatives and 
tranquillisers•
Nasal sprays Hypertensive crises with 
monoamine oxidase inhibitors.
Tonics Alcohol content may cause 
disulfiram-like (Antabuse) 
reactions with a variety of 
drugs, excess central nervous 
system depression with 
sedatives and tranquillisers 
and haemorrhage with 
anticoagulants.
TABLE 6 Examples of possible interactions between o-t-c 
drugs and prescribed drugs.
Alcohol, although used almost exclusively for social and not 
therapeutic purposes, may modify the effect of certain drugs* This 
may call for considerable restraint in its use* The combination of 
alcohol and central nervous system depressants has commanded much 
attention mainly because of its relationship to driving, accidental 
deaths and suicide. Alcohol may also cause adverse effects in 
combination with antidepressants, anticoagulants, hypotensive agents, 
vasodilators, disulfiram-like agents, (e.g. metronidazole and 
griseofulvin) and hypoglycaemic agents. (Rosinga 1968; Kater et al 
1969; Gessner and Cabana 1970; Parker 1970; Rubin et al 1970;
Waller 1971; Sellers et al 1972a, 1972b; Gessner 1974; Linnoila 
et al 1974; Stockley 1974)*
An extremely useful annotated bibliography of the scientific 
literature relating to the interaction of alcohol and other drugs 
has been prepared by the Canadian Addiction Research Foundation 
Documentation Department (Polacsek et al 1972).
In view of the risks presented by such combinations, the doctor 
is obliged to emphasise the dangers of these interactions at the 
expense of the pleasures of drinking* Even though some control over 
the utilisation of non-prescription drugs could be exercised by the 
retail pharmacist, similar consideration could not be expected from 
the licensee in relation to the sale of alcohol# Nor can any 
effective control be placed on the supply of drugs and alcohol from 
other, often misguided but well-meaning sources such as the family, 
relatives, friends and neighbours. Thus, unless patients are advised 
by well-informed doctors and pharmacists, the aims of effective therapy 
may easily be thwarted by the intervention of unnecessary drug 
interactions.
2.4* EXAMPLES OF UNMONITORED MULTIPLE DRUG THERAPY
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Varney (1974) drew attention to the confusion and potential harm 
of unmonitored multiple drug therapy when he graphically described an 
elderly lady rendered immobile by the large number of drugs which had 
been prescribed for her. These included (l) dextropropoxyphene and 
paracetamol (toistalgesic1), (2) phenylbutazone, (3) aspirin, codeine 
and caffeine, (4) aspirin, magnesium carbonate and aluminium glycinate, 
(5) aluminium hydroxide, (6) dicyclomine hydrochloride, doxylamine 
succinate and pyridoxine hydrochloride (tDebendoxl), (7) alkaloids of 
belladonna leaf, ergotamine tartrate, phenobarbitone and ascorbic acid 
(’Autergal1), (8) medazepam, (9) prochlorperazine, (10) calcium lactate, 
(11) sodium chloride, (12) 'Senokot*, (13) ferrous sulphate, (14) 
proteolysed liver and vitamin B^, (15) liquid paraffin and (16) 
chlorpromazine linctus. This elderly lady was, therefore, taking a 
total of 25 different drugs but was "managing to get them all down".
A simple analysis of her treatment shows that she was taking:
6 analgesics 3 sedatives
3 antacids 1 hypnotic
2 anticholinergics 2 laxatives
1 antihistamine 4 vitamins/haematinics
1 ergotamine preparation 2 "salts".
Varney left it to the reader to speculate on the number and 
variety of possible interactions which could take place from this 
combination of drugs. It is certain, however, that excessive central 
nervous system depression was a prominent feature. After admission 
to hospital all tablets were stopped and ten days later she returned 
home, fully mobile.
Similar cases have been observed by the present author. The 
most dramatic example was provided by an elderly lady who presented 
the bottle shown in Figure 1 to ward nursing staff on her admission 
to hospital. The bottle contained her current ’^ medicine", a variety
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FIGURE I An example of unmonitored 
multiple drug therapy.
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of preparations with the instruction "The Capsules, one four times 
a day". The patient was obviously totally confused about her 
treatment, which consisted of the seven preparations shown in Hgure 2 
namely, indomethacin, a sustained release form of ferrous sulphate, 
amylobarbitone, dihydrocodeine, "Distalgesic" (a compound preparation 
of paracetamol and dextropropoxyphene) a sustained release form of 
glyceryl trinitrate combined with phenobarbitone and one preparation 
which could not be positively identified, but was probably promazine.
Thus the seven preparations contained nine active ingredients.
Although no serious adverse effects would have arisen from this 
particular combination, it was disturbing to find therapeutics reduced 
to such an arbitrary level.
While it cannot be disputed that the multiple pathology occurring 
in elderly patients may indicate a number of different therapeutic 
approaches, Davison (1972) recommended that complicated drug schedules 
should be resisted, especially for those living alone or suffering 
from intellectual impairment. Three drugs was the maximum number that 
an elderly person could be expected to cope with.
2.5# CONCLUSIONS
2he considerable expansion in the pharmaceutical industry over the 
last 10-20 years has reflected itself in the proliferation of drug 
therapy given to individual patients. This has been complicated by 
the ready availability of non-prescription products and the public *s 
determination to indulge in self-medication. At the same time 
polypharmacy has been shown to be potentially dangerous because of 
its association with an increased incidence of adverse drug reactions 
based partly on drug interactions.

C H A P T E R  3
FACTORS MODIFYING DRUG RESPONSE IN MAN
15
3* FACTORS MODIFYING DRUG RESPONSE IN M M
An understanding of the mechanisms involved in drug interactions 
is essential for their classification, interpretation, prevention and 
treatment* It is also essential to recognise that the overall 
clinical importance of a drug interaction will depend on the interplay 
of several other factors that modify drug response in man, e*g* 
genetic, environmental and pathophysiological factors, allergy and 
idiosyncrasy, age, sex and body weight, and various prescribing 
factors such as time and route of administration and dosage (Figure 3).
3.1. GENETIC FACTORS
The first systematic account of the influence of heredity on 
drug response was given by Kalow (1562). In the introduction to 
his book, Pharmacogenetics-Heredity and the Response to Drugs, Kalow 
stated that not all men react alike to a given dose of a drug, nor do 
all animals* This variation in response from individual to individual 
within a species had been regarded for a long time as a nuisance and 
a stumbling block in the assessment of drug action. Fortunately, 
the common interest of geneticists and pharmacologists in this subject 
created the discipline of pharmacogenetics, which has attempted to 
define precisely the hereditary influences that modify drug response, 
and also the genetically determined conditions which may be 
precipitated by drugs, e.g. the acute attack of porphyria caused by 
barbiturates (Eales and Linder 1962)* Genetic factors, therefore, 
may effect drug metabolism and response, giving rise to an important 
source of individual variability.
An excellent example of this was provided by Hammer and Sjoqvist 
(1967). They gave the tricyclic antidepressants desmethylimipramine
DRUG
OTHER DRUGS 
(prescribed)
■h
o -t-cpreparations
t
GENETIC
FACTORS
ALLERGY
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impairment
FIGURE 3 The factors which contribute to the response of a patient 
to a drug. The small cartoon at the top of the figure 
represents the environment.
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and nortriptyline in standard doses to a group of patients, and 
measured steady-state plasma concentrations. Marked interindividual 
differences were found, with 30-fold differences in the steady-state 
levels attained. This was taken to indicate large individual 
differences in the activity of drug metabolising enzymes in the 
patients studied. Subsequent work showed that the steady-state 
plasma level, rather than the dose employed, determined the 
pharmacological effect of tricyclic antidepressants in individual 
patients (Freyschuss, Sjoqvist and Tuck 1970; Xsberg et al 1970 >
1971*) The mechanisms behind these interindividual differences were 
explored further by Alexanderson, Sjoqvist and Price Evans (1969) 
when they undertook a pharmacogenetic study in a group of healthy 
twins from the Stockholm area. Their aim was to assess the relative 
contribution of genetic and environmental factors, particularly 
concomitant drug therapy, to the determination of steady-state levels 
of nortriptyline. Nineteen identical (monozygotic) and 20 fraternal 
(dizygotic) sets of twins between 45 and 51 years of age were given 
nortriptyline orally in a dose of 0.2 mg/kg body weight three times 
daily for eight days. Steady-state plasma concentrations of 
nortriptyline were determined at the end of this period. The entire 
group showed a 10-fold difference in these levels (8-78 ^ ig/ml)
(Figure 4).
Identical twins not treated with other drugs showed no significant 
differences between steady-state plasma concentrations (Figure 5) in 
contrast to a similar group of fraternal twins who showed significant 
intrapair differences (Figure 6). Identical twins who were on 
treatment with various other drugs during the study (Figure 7) lost 
the intrapair similarity shown by their counterparts not taking other 
drugs, and fraternal twins exposed to other drugs (Figure 8) showed 
even greater differences in steady-state levels than those not exposed.
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Purthermore, identical twins treated with various drugs containing 
barbiturates had considerably lower steady-state plasma concentrations 
of nortriptyline than untreated control twins.
The marked differences between identical and fraternal twins 
not previously exposed to other drugs indicated that most of the 
variability in nortriptyline steady-state levels was genetically 
determined, probably a reflection of individual rates of drug 
metabolism. Exposure to other drugs also influenced the steady- 
state plasma concentration of nortriptyline, which in a given patient 
may therefore be determined by a combination of genetic and 
environmental factors.
The Stockholm study confirmed the results of a series of studies 
on normal adult Caucasian twins living in the V/ashington D.C. area. 
(Vessell and Page, 1968a, 1968b, 1968c; Cascorbi et al 1971?
Vessell, Page and Passananti 1971? Vessell et al 1971)• Single oral 
dose studies were performed with phenylbutazone, antipyrine, 
bishydroxycoumarin and ethanol, a group of agents known to be handled 
almost exclusively by biotransformation rather than by excretion of 
unaltered parent drug. Plasma half-lives, rather than steady-state 
levels, were measured because chronic administration of these agents 
would produce an increase in activity (induction) of the hepatic 
microsomal drug-metabolising enzymes, (Conney 1967; Breckenridge and 
Orme 1971 )• Ihis would, of course, obscure any genetically determined 
differences in rates of drug metabolism. Intratwin differences in 
half-lives were appreciably greater in fraternal than identical twins, 
and it was concluded that genetic rather than environmental factors 
maintained large individual differences in metabolic rates of 
elimination of these drugs.
It is clear, therefore, that genetic factors may be responsible 
for large intraindividual differences in rates of metabolism and
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elimination of many commonly used drugs. Unless these factors are 
taken into account, inappropriate doses of some drugs may be prescribed, 
which could lead to unexpected results, including adverse drug 
interactions. As Price Evans (1969) ^as pointed out, pharmacogenetic 
studies have emphasised the necessity of treating patients on as 
personal a basis as possible with respect to choice of drugs and dose 
schedules.
3.2. EN7IR0UMENTAL FACTORS
Sjoqvist and Alexanderson (1972) placed drugs in an environmental 
perspective by referring to their overconsumption as a form of 
’’internal pollution”. External, or atmospheric pollution, may also 
exert a considerable influence on rates of drug metabolism. It has 
been established that a variety of chemicals found in the environment, 
such as chlorinated hydrocarbons and insecticides can stimulate drug 
metabolism, (Hart and Pouts 1963 J Conney 19^7> 1969} Conney et al
1967).
Eolmodin, Azamoff and Sjoqvist (1969) found that workers who 
were occupationally exposed to a mixture of insecticides, including 
D.D.T., chlordane, and lindane, had shorter plasma antipyrine half- 
lives than unexposed controls. Ihis suggested induction of antipyrine 
metabolism and supported similar findings in experimental animals 
exposed to chlorinated insecticides (Kblmodin-Hedman, Alexanderson 
and Sjoqvist, 197l). Thus environmental factors may play a role in 
regulating the rate of drug metabolism, and may lead to unexpected 
variations in the plasma level and tissue content of some drugs.
This may in turn make a contribution to the evolution of drug 
interactions.
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,3.3. PATHOLOGICAL FACTORS
Against this background of individual variability due to genetic 
factors and the environment must be set the effects of disease. For 
many years, dosage regimes have been derived from the study of normal 
healthy volunteers, but there may be no comparison between such 
volunteers and ill patients with respect to their drug handling.
3.3.1* Renal disease
The importance of renal function in the determination of drug 
dosage is clearly documented for many antibiotics and other drugs, 
such as digoxin, that are excreted mainly unchanged in the urine.
If the clearance of a drug is largely dependent on renal excretion, 
its plasma half-life will be prolonged in patients with renal 
impairment. Thus changes in renal function will modify a number of 
pharmacokinetic processes which may lead to unanticipated drug effects 
or drug interactions. The dosage schedule must, therefore, be 
modified in such a way, that the drug level resulting in patients 
with kidney disease is the same, and is reached after a similar time 
interval as in patients with normal renal function, (Dettli, Spring 
and Ryter 1971)*
Pharmacokinetic models
Simplified pharmacokinetic models can be used to avoid drug 
toxicity due to accumulation in such patients, provided that the 
renal function is known. The simplest description of the time course 
of circulating drug levels is provided by the one-compartment open 
model (Figure 9) where and are first order rate constants for
ADMINISTRATION
urine 
ELIMINATION 
extra-renal
Ka
D — I
FIGURE 9 One-compartment open body model. K is the rate constant€1
for absorption of drug (d ) from the gut into the body.
in the simplified lower diagram is the sum of the rate
constants K and K which characterise drug elimination by u m & j
renal and extra-renal routes respectively. It is assumed 
that all drug transfer processes are first-order, i.e. 
are concentration dependent.
BODY
Ku
Ka A
BODY
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i
excretion of unchanged drug by the kidneys, and drug elimination by 
all other extra-renal routes respectively. .« It follows that 
k^ + « Kq, the overall elimination rate constant, and it is
assumed that the reduction of the overall elimination rate in patients 
with renal disease is entirely due to a reduction of the renal 
elimination rate, while the extra-renal elimination rate remains 
unaltered. In severe renal impairment, k^ approaches zero, and the 
overall rate constant for drug elimination approaches
Analogue Computer Simulation
The effect of altered renal function on circulating drug levels 
and urinary excretion, based on the one-compartment model, can be 
simulated by analogue computation. Using a Limrose AHT 00^0 Analog 
Tutor (Figures 10 and 11), programmed as shown in Figure 12 the 
relationships shown in Figure 13 were derived to demonstrate these 
effects. Analogue computation differs from digital computation in 
that it deals with continuously varying voltages rather than discrete 
integers or digits. The input of the analogue computer is a voltage 
(i.c.(D) in Figure 12, representing the dose of a drug) that 
subsequently varies with time, determined by setting potentiometers
and k^ in Figure 12, set to the control rates 
of absorption, extra-renal elimination and renal elimination 
respectively). The output is also in the form of a voltage which 
changes with time, visualised either as a repetitive sweep on an 
oscilloscope, as shown in Figure 11, or as a graph traced on a suitable 
plotter. Figure 13 was prepared from such a graph. A single dose, D, 
in the gut at time zero is absorbed into, and lost from, the body at 
a rate proportional to the residual drug concentration according to 
the following relationships (extra-renal elimination is ignored for
in the circuit (K , K
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administered into the gut in a one-compartment system, 
i.e. (d ) is the potentiometer connected to a constant 
voltage (-10v) which determines the dose. Ka> Km and 
are potentiometers which determine absorption, extra- 
renal and renal elimination rates (cf. rate constants in 
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drug in the body and the amount eliminated by extra-renal 
and renal routes respectively. GI, M, B and U are 
operational amplifiers acting as integrators.
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the sake of simplicity).
d^dt°dy  ^ " Ka-D(sllt) “ ^HCtody)
- \tiwr)
Hie computer programme resulting from these equations is seen in 
figure 12. After an identical dose, reduction of renal function by 
a factor of 5 (corresponding to values of 1 and 0.2) caused a 
significant increase in the amount and persistence of drug in the 
plasma. Hie respective half-life values were 42 minutes and 3-J- hours.
Dosage prediction nomograms
In a subject with normal renal function, the fraction of absorbed 
dose excreted unchanged in the urine, f, is given by:
* - - i -
Hie values of and can be readily calculated from the observed 
elimination of unchanged drug in the urine of subjects with normal 
renal function, and this information has recently been utilised by 
Welling, Craig and Kunin (1975) to construct nomograms which relate 
the elimination of a drug to renal function, as assessed by the 
endogenous creatinine clearance.
Similar measures have been proposed by Dettli and his colleagues 
to derive elimination rate constants in individual patients that can 
be used to calculate dosage adjustments (Dettli 1970a, 1970b; Dettli, 
Spring and Ryter 1971) and by Mawer and his colleagues, specifically
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in relation to the use of gentamicin in renal impairment (Mawer et al 
1974a, 1974b)• The latter group designed a nomogram based on simple 
bedside parameters such as age, weight, sex and plasma creatinine 
level, (Figure 14)*
All these methods are based on assumptions derived from the one- 
compartment open model (Figure 9), in particular that drug clearance 
is linearly related to creatinine clearance* Hialkin et al (1975)> 
however, have suggested that digoxin clearance may be more closely 
related to that of urea than to that of creatinine.
Digoxin pharmacokinetics
Compartmental analysis of digoxin kinetics (Sumner, Russell and 
Whiting 1976) demonstrated that digoxin conforms to the three- 
compartment model shown in Figure 15* It can be seen that this is 
rather more complex than the single compartment model* In parallel 
with the central compartment, which represents plasma water and those 
fluid spaces with which free (non protein bound) drug achieves rapid 
equilibrium, are two "side” compartments, referred to as the shallow 
and deep compartments. These represent various body tissues, and 
while no definite anatomical significance can be attributed to them, 
they denote tissues in which the myocardial receptors, sensitive to 
the action of digoxin, are located. K is the absorption rate8r
constant, the renal elimination rate constant, and the extra- 
renal elimination rate constant, largely accounted for by biliary 
excretion. K^, Kg, K^ and K^ are rate constants which identify the 
rates at which digoxin diffuses into and out of the tissues, and the 
rates of binding to, and dissociation from, drug receptors* FJven 
this model could be improved by introducing "feed-back” loops to 
represent the entero-hepatic circulation of digoxin and its salivary
GENTAMICIN DOSAGE
I ' l l | - r ~ T V i I i I i | i
80 70 60 50 40 30 20 years
B
FIGURE 14 Nomogram for the determination of gentamicin dosage.
A straight line is drawn between serum creatinine 
concentration (scale A) and age (scale B). The
point of intersection on line C is marked. A straight
line is then drawn between this point and the body weight 
(scale D). The points at which this line cuts the dosage 
lines L and M are marked and the appropriate loading dose 
(mg), maintenance dose (mg) and interval (hr) are read off.
From Mawer et al 1974 ♦ reproduced by kind permission of 
Professor G.E.Mawer and the publishers, Macmillan Journals 
Ltd.
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FIGURE 15 Three compartment model for digoxin kinetics. See text
for description of compartments. All rate constants are
assumed to be first-order; K& , and as in Figure 9,
K^ , and describe uptake and release from the
shallow and deep compartments.
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Compartment 3  
—  ("deep")
Compartment 2 
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FIGURE 16 Predicted time course of digoxin levels in the shallow and
deep compartments (R.H. scale) in relation to observed changes 
in the central compartment (plasma, L.H. scale) according to 
the three-compartment model shown in Figure 15*
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excretion,
Thus the time course of circulating drug is determined by the 
movement of digoxin between the various compartments and does not 
depend solely on absorption and elimination. An important rate 
limiting step is the release of drug from the deep compartment, 
characterised by the rate constant K^« Overall clearance from the 
body appears to depend largely on glomerular filtration, but a 
significant contribution is made by extra-renal routes, notably the 
bile.
The predicted time course of digoxin levels in the shallow and 
deep compartments, in relation to the central compartment, is shown
in Figure 16, derived from mathematical analysis of the concentration-
3
time relationships of H-digoxin in blood, urine and faeces, following 
its intravenous administration to four healthy male volunteers, aged 
between 27 and 35 years. The intravenous plasma concentration data 
were fitted to the triexponential function
— X_ t - A~t **A-stc-je 1 + 2 + c^e 3
using a non-linear least squares fitting programme, BID X85 (Bfl) 
Biomedical Computer Programs, 1968) on an IBM 370/158 computer# It 
was found that three exponentials were required to give a satisfactory 
fit to the data, and therefore any compartmental model used to fit the 
data had to contain a minimum of three compartments, excluding the gut. 
The model shown in Figure 15 was considered to be consistent with this 
analysis.
The changes in digoxin concentration in the tissue compartments 
shown in Figure 16 correlated well with the pharmacodynamic effects of 
the drug observed by other workers (Weissler et al 1972; Davidson and 
Gibson 1973; Reuning, Sams and Notari 1973) which lends support to the 
validity of this model.
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Analysis of this type can subsequently be used to calculate 
individual dosage regimes to suit varying degrees of renal function.
Extra-renal mechanisms
The extra-renal elimination of drugs, which assumes increasing 
importance in renal failure, may not remain constant and may be subject 
to individual variations. Reidenberg and Katz (1973)» for example, 
described a uraemic patient with an 8-day half-life for digoxin, compared 
with the 4.4 days normally found in uraemic patients. This indicated 
substantial slowing of the extra-renal elimination of the drug, and was 
probably' due to coexisting liver disease. Previous studies by Bloom 
and Help (1966) and Doherty and pLanigan (1967) had also shown 
substantial individual variation in faecal excretion of digoxin.
Other processes which may be altered by uraemia are drug metabolism 
(Reidenberg, James and Bring 1972; Reidenberg 1974)? drug plasma 
protein binding (Odar-Cederlof, Lunde and Sjoqvist 1970; Reidenberg 
et al 1971J Reidenberg and Affrime 1973» O'Malley et al 1975) and 
tissue sensitivity to drugs (Reidenberg 1971)*
In uraemic patients, however, in whom dose adjustment is most 
important, it is acceptable to assume a linear relationship between 
drug elimination and creatinine clearance or glomerular filtration 
rate when a drug is normally eliminated principally by the kidneys. 
Impaired renal function may, however, modify a number of pharmacokinetic 
processes, and predictions based on this linear relationship must be 
seen as only a first approximation to ideal dosage. It is clear, 
therefore, that unless the influence of renal function on the clearance 
of many drugs is recognised, accumulation may lead to toxicity per se 
or to drug interactions as a result of altered kinetic processes and 
abnormally high concentrations of drugs.
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3*3*2* Liver disease
The role of liver disease in altering rates of drug metabolism 
in man is controversial. Studies are hampered by the considerable 
overlap in kinetic variables (which reflect drug metabolism) between 
normal patients and patients with liver disease. Two approaches 
have been used to study this problem, the measurement of drug 
metabolising enzyme activity in liver biopsies, and the study of 
drug kinetics in patients. Schoene et al (1972) estimated the 
content of cytochrome P-450 in liver biopsies taken from patients 
with severe hepatitis or cirrhosis* A reduction in cytochrome 
P-450 was demonstrated, together with a reduction of the 
demethylating activity of the drug-metabolising enzymes* Leewy 
et al (1970), on the other hand, could not correlate hepatic 
pentobarbital hydroxylase activity with liver function in viral 
hepatitis or alcoholic liver disease* Such in vitro studies, 
however, do not take into.account the total hepatic capacity of 
drug metabolism, and are probably of limited value. Another 
difficulty is shown by the lack of correlation between hepatic 
enzyme content and variations in rates of drug metabolism when 
different species are compared.
In vivo studies in hepatic disease have also yielded conflicting 
results, with reports of prolongation of the half-life of some drugs 
not confirmed by others. The inconsistency of these results has 
been attributed to the lack of reliable methods for the quantitative 
estimation of reduced liver function, and to genetically determined 
interindividual variations in drug metabolism.
Evidberg, Andreasen and Raneck (1974) attempted to define the 
position more clearly by using a more sensitive index of liver 
function, the galactose elimination capacity (G.E.C.) (Tygstrup, 19^4)*
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Reduction of G.E.C. in patients with liver disease (alcoholic and 
idiopathic cirrhosis) was significantly correlated with changes in 
the apparent elimination rate constant (or plasma half-life) of 
phenylbutazone, which undergoes almost complete metabolic 
transformation in the liver (Figure 17)•
These results provided preliminary evidence for a correlation 
between liver function and the rate of metabolism of a drug, but 
further research is needed to assess the contribution of other factors 
such as changes in plasma protein binding and alterations in the 
disposition of drugs in liver disease. As Wagner (l97l) has pointed 
out, changes in plasma half-life need not necessarily reflect changes 
in the rate of drug metabolism, and there is now an increasing amount 
of evidence to show that the binding capacity of serum proteins for 
various drugs is reduced in patients with liver disease (Powell and 
Axelsen 1972; Affrime and Reidenberg 1973; Reidenberg and Affrime 
1973» Reidenberg 1974; Hooper et al 1974; Affrime and Reidenberg 
1975; Wallace and Brodie 1976).
3.4* EFFECT OF AGE AND SEX
Apart from the major factors already discussed, drug response 
may be partly dependent on basic physiological factors such as age 
and sex. No sex difference in drug metabolism had been found until 
OfMalley et al (l97l) reported a significant reduction in antipyrine 
metabolism in a group of men, aged 17-52 (mean 27*4) years compared with 
a group of women aged 16-49 (mean 25*3) years. These workers also 
observed a reduced capacity for drug metabolism in elderly patients.
More recently, alterations in warfarin protein binding and phenytoin 
clearance have also been described in the elderly (Hayes, Langman and 
Short 1975a, 1975t>)« This will be discussed further in Chapter 4»
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3.5. biophabmaceutical factors
Variation in drug absorption may also assume considerable 
importance and a great deal of attention has been focussed recently 
on the influence which some physico-chemical properties of drugs 
exert on their behaviour in the gastro-intestinal tract. Release 
and availability of a drug from its pharmaceutical formulation in 
vivo depends on a number of factors:
lipid solubility 
water solubility 
degree of ionisation 
chemical stability 
molecular weight 
pharmaceutical formulation.
These factors largely determine the amount of drug available, the 
rate of its release from the dosage form, and the rate of absorption 
through the intestinal mucosa. Different preparations of a drug 
containing the same amount of active chemical are regarded as 
"chemically equivalent", but they cannot be considered "generically 
equivalent" unless they have identical biological activity under 
clinical conditions.
A major advance in pharmacotherapy during the last few years has 
been the demonstration of lack of generic equivalence, implying 
incomplete and variable biological availability (bioavailability) of 
drug products. This has had important repercussions on both the 
pharmaceutical industry and clinical practice. Variations in the 
bioavailability of drugs obviously placed clinicians in an untenable 
position, especially when dosage was relatively critical - as in the 
case of digoxin. The first suggestion that digoxin tablets from 
several sources might show differing bioavailabilities was made in
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Einland by Manninen, Melin and Hartel (1971 )• Shortly after
Lindenbaum et al (1971) in the United States, provided further 
evidence for this lack of equivalence, and many other studies have 
subsequently confirmed this. Even variations in the bioavailability 
of digoxin from the same manufacturer provided a degree of 
consternation (Stewart and Simpson 1972; Whiting, Rodger and Sumner 
1972). It was soon recognised that this variability was largely 
related to the rate of dissolution of digoxin tablets (Lindenbaum 
et al 1973; Johnson et al 1973) and standardisation of this 
pharmaceutical determinant of bioavailability was urgently required.
(ihe rate of dissolution characterises the rate at which a drug 
dissolves in gastro-intestinal fluid following its release from 
solid dosage form). For sparingly water-soluble drugs like digoxin 
the dissolution rate was shown to be an important rate limiting 
step in absorption and subsequent biological availability (Beckett 
and Cowan 1972; Eraser, Leach and Poston 1972).
A convincing demonstration of the correlation between dissolution 
rate measured in vitro, and bioavailability assessed in vivo by 
measuring the area under the six hour concentration/time curve in 
healthy volunteers was presented by Eraser et al (1973)• Shaw et al 
(1973) performed a similar study in patients, and evaluated seven types 
of digoxin (0.25 Eg tablets) in common use in the United Kingdom.
They concluded that measurement of in vitro dissolution rates appeared 
to be a valid method of ensuring that different brands of digoxin 
were equally effective. ELgures 18 and 19 show typical dissolution 
profiles and corresponding serum concentration/time curves respectively, 
(from Eraser et al 1973).
Ihe marked differences in bioavailability revealed by these 
reports was due to the effect of different production methods on the 
particle size of digoxin (Jounela and Sothmann 1973? Shaw et al 1973;
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FIGURE 18 Dissolution profiles of two different oral digoxin 
preparations. Redrawn from Fraser et al 1973 by 
kind permission of the authors and the Journal of 
Pharmacy and Pharmacology.
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FIGURE 19 Serum concentration profiles corresponding to the two 
digoxin preparations shown in Figure 18, Redrawn 
from Fraser et al 1973, by kind permission of the 
authors and the Journal of Pharmacy and Pharmacology.
Jounela, Pentikainen and Sothmann 1975) and. the problem has now been 
resolved by the introduction of a new standard ensuring a uniform 
rate of release of digoxin, i.e. at least 75$ of the stated tablet 
content of digoxin should be released within one hour*
In 1972, Doluisio stated "At present, there are no enforced 
standards which will insure bioavailability11. Experience with digoxin 
inequivalence has been of considerable value as it has led to some 
improvement in this situation and a greater awareness of the problem 
as a whole. Ihis is important as every effort should be made to 
minimise variations in drug availability due to pharmaceutical factors, 
as such variations may be compounded by a number of other factors. 
Koch-Weser (1974) identified the following important ones:
1. Drug characteristics such as interaction before gastro­
intestinal absorption, biotransformation in the intestinal 
wall or in the liver ("first-pass effect") and incomplete 
absorption.
2. Interaction with other substances in the gastro-intestinal 
tract, such as food and drugs.
3. Patient characteristics such as gastro-intestinal pH, 
motility, perfusion, flora, structure and malabsorption 
states.
Genetic factors have even been implicated, as Levy and Hollister (19&4) 
described "slow” and "rapid” absorbers of aspirin and Prescott and Nimmo 
(1971) observed a similar phenomenon with phenacetin, paracetamol and 
tetracycline. Numerous references relate to generic inequivalence 
with a variety of other drugs including chloramphenicol, nitrofurantoin, 
nortriptyline, phenylbutazone, phenytoin, tetracyclines, tolbutamide and 
warfarin.
It is clear, therefore, that drug response in man is determined by 
the interplay of several important factors and if drug interactions are
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to be interpreted correctly they should he regarded as one contributory 
factor to this response#
3.6. CONCLUSIONS
The individual patient given a combination of drugs presents a 
unique set of conditions under which the drugs may interact. The 
effects of renal and hepatic disease, age, sex, genetic influences and 
bioavailability are some of the factors which must be taken into account 
and may often assume greater importance than the effects of drug 
interaction itself. Indeed, the same combination of drugs may 
produce an adverse effect in one patient and no observable effect at 
all in another.
C H A P T E R  A 
MECHANISMS OP DRUG INTERACTION
4. MECHANISMS OF DRUG INTERACTION
4.1. INTRODUCTION
A true appreciation of the significance of drug interactions 
demands (a) an awareness of their contribution to the overall drug 
response in man and (b) a knowledge of their mechanisms. The 
factors responsible for (a) have already been discussed, and drug 
interactions have been placed in their correct perspective. Because 
of the multiplicity of factors involved, it is not surprising that 
some interactions may not be recognised and may fail to attain much 
clinical significance. They may also be obscured by a large 
therapeutic index or a therapeutic effect which is difficult to 
measure quantitatively. But interactions will be obvious if they 
occur with drugs which have readily measured effects, or which require 
regular monitoring, e.g. anticoagulants and hypoglycaemic agents. 
Moreover, the recent availability of assays for measuring plasma 
levels of several drugs with low therapeutic indices and difficult end 
points has allowed recognition and investigation of several important 
drug interactions, including those with digitalis glycosides, anti- 
arrhythmic agents and antiepileptic drugs. Although toxicity may be 
a relatively dramatic outcome of a drug interaction, a decrease in 
effect may be just as important. Thus, loss of hypotensive effect or 
failure to control an arrhythmia or epileptic seizure can be as serious 
a result of drug interactions as drug toxicity.
Drug interactions can occur in any of the three main phases of 
drug action shown in Hgure 20.
The •pharmaceu t ical or drug release phase relates to the physical 
processes which release the drug in a molecular, dispersed form from 
the pharmaceutical preparation, and make it available for absorption.
dosage form
_ t __________
PHARMACEUTICAL PHASE
I
drug available 
for absorption
 A.____
PHARMACOKINETIC PHASE
I
drug available 
for action
 A _______________________
PHARMACODYNAMIC PHASE
♦
response
FIGURE 20 The three phases of drug action*
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The pharmacokinetic phase comprises the processes involved in 
the distribution and elimination of a drug, either by biotransformation 
or excretion, and determines the level of a drug in the body fluids and 
tissues.
[Che pharmacodynamic phase comprises the induction of effect and 
subsequent response in target tissues*
Thus drug interactions can conveniently be referred to under three 
headings - pharmaceutical, pharmacokinetic and pharmacodynamic.
4.2. INTERACTIONS IN THE PHARMACEUTICAL PEASE
The rate or amount of drug absorbed may be significantly altered 
by interactions in the gastro-intestinal tract. Two mechanisms may 
be responsible for this;
(a) Complex formation
(b) Riarmacological interference with gastro-intestinal function.
4.2.1. Complex formation
Many organic drug molecules can form relatively weak reversible 
associations with one or more molecules of another drug, surfactant or 
protein (Martin, Swarbrick and Cammarata 1969). This results in drug 
complexes which may differ appreciably from the free drug with respect 
to such physical-chemical characteristics as solubility, diffusivity, 
size, electrical charge and lipoid-water partition coefficient. Such 
differences imply corresponding differences in the absorbability of the 
free drug and drug complex from the gastro-intestinal tract. 
Unintentional and -unanticipated interactions of drugs with other 
constituents of their dosage form, with ingested food or with other 
drugs may lead to the formation of poorly absorbed complexes and
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consequent relative unavailability or drug inactivation. Two examples 
of such adverse interactions are the poor absorption of tetracycline 
in the presence of calcium (Emin and Finland 1961), iron and milk 
(Price et al 1957; Neuvonen et al 1970; Mattila et al 1972) and the 
ineffectiveness of an orally administered iron-carbohydrate complex 
(Diamond et al 1963), In their study Mattila et al (1972) derived 
important implications for this type of interaction. There was no 
doubt that ferrous sulphate interfered with tetracycline absorption 
(Figure 21, from Neuvonen et al 1970), The two drugs administered 
simultaneously would result in reduced plasma levels of the antibiotic. 
But Mattila and colleagues pointed out that if the drugs were given 
separately with an interval of about three hours between them, this 
interaction could be avoided.
It is rather difficult to assess the overall clinical significance 
of the iron-tetracycline interaction when tetracycline is often 
prescribed for infections which are not responsive to this antibiotic. 
However, simultaneous therapy with tetracycline and iron, whether in 
•’tonic11 form or tablets, may be instituted in prolonged or recurrent 
infections, and proper timing of these drugs will be important, 
particularly in debilitated patients who need adequate antibiotic levels.
It is also interesting to note that Greenberger, Ruppert and 
Cuppage (1967) demonstrated that iron absorption may be interfered with 
as well when in combination with tetracycline. Experiments performed 
in rats, both in vivo and in vitro, showed that the inhibitory effect 
of tetracycline was dose dependent, and was only observed after large 
doses. Both complex formation and impaired intestinal iron transport 
were implicated. Iron preparations also form poorly soluble 
precipitates when combined with antacids or phosphates.
Adsorbents such as activated charcoal and kaolin, and astringents, 
may delay or inhibit absorption from the intestine. A good example
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with 200 mg of ferrous sulphate, (Five subjects in each group). 
From Neuvonen et al 1970, by kind permission of the authors 
and the Editor of the British Medical Journal,
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was provided by Wagner (1966) when he demonstrated the delay in 
lincomycin absorption when combined with the intestinal adsorbents 
kaolin and pectinic acid. More recently, Einnion and McDermott (1972) 
suggested that the absorption of digoxin could be interfered with by 
the antacid preparation "Maalox" and the antidiarrhoeal preparation 
"Xaopectate”. Both these preparations adsorbed digoxin in vitro and 
preliminary human studies showed a marked effect on blood digoxin 
levels when digoxin tablets were administered with these two medicines.
4*2.2, Pharmacological interference with gastro-intestinal function
An important distinction must be made between interactions that 
alter the rate of drug absorption and those that increase or decrease 
the total amount of drug absorbed, since the consequences may be quite 
different.
Analogue computer simulation
This distinction can be conveniently demonstrated by analogue
computation and Hgures 22 and 23 were derived from the computer
programme shown in Hgure 12 to demonstrate the effect of changes in
the rate constant of absorption (K ) and the fraction absorbed ona
blood levels and urinary excretion. Hgure 22 shows that changes in 
the rate of absorption with JC values of 1, 0.5 and. 0.2 do not influence£L
the actual amount of drug absorbed, but delay and reduce the peak plasma 
concentrations attained. The urinary excretion curves reflect the 
different rates of absorption but show that there are no differences 
in the total amount excreted* It is obvious from Hgure 23 that a 
decrease in the fraction absorbed is equivalent to a decrease in the 
dose given, with obvious clinical implications. Complex formation will
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have this effect.
Although a drug may eventually be completely absorbed, it may be 
absorbed so slowly that:
(a) it may never reach effective blood levels
(b) the rate of onset of effect may be delayed
(c) the effect may be unduly prolonged*
An important distinction must be made between types of drugs and
clinical situations when decreased rates of absorption are clinically
significant and those where this type of interaction may occur but is
of little or no concern. In general, delayed absorption is usually
important for drugs that are given as a single dose in clinical
situations requiring a rapid onset of effect, e.g. analgesics or
hypnotics. Delayed absorption may also be important in the case of
drugs with a short biological half-life (or rapid elimination) such
as procainamide, as therapeutic concentrations may never be attained.
Hgure 24 was derived on the analogue computer to demonstrate this.
Drug A has a relatively short half-life of 42 minutes compared with
drug B which has a half-life of seven hours. Absorption rates differ
by a factor of 2.5> i*e* each drug is shown with K values of 1 and 0*4»a
The slower rate of absorption (K ■ 0*4) has had much less effect on the
3>
peak attained by drug B, which is reduced by 21$, than on that attained 
by drug A, which is reduced by 41$* Thus if the absorption of a rapidly 
eliminated drug is delayed for any reason, its therapeutic effect may be 
seriously compromised. On the other hand the rate of absorption of 
compounds with relatively long half-lives such as digoxin, has little 
influence on the blood levels achieved. The mean steady-state blood 
level in these circumstances depends much more on the fraction of drug 
absorbed than on the relative rate of absorption. Two circumstances in 
which aspirin is used will illustrate these points. Food affects the 
rate of absorption of aspirin but not the total amount absorbed. This
°/o
 
AD
M
IN
IS
TE
R
ED
 
DO
SE
 
IN 
P
LA
S
M
A
FIGURE
100-
B
100n
5 0 -
5 0 -
DRUG B
DRUG A
0 642 8
TIME IN HOURS
24 Analogue computer simulation of the relationship between 
the rate of absorption and the rate of excretion of drugs, 
Kq (A) » lh \  tj 42 minutes
K0(b ) = 0*lh \  7 hours
Absorption of both drugs is reduced by 60% :
A
Ka “ 1 ! Ka = 0.4
B K = 1 j •«*••••••• K ■ 0*4a a
Peak height A is reduced by 41$
Peak height B is reduced by 21$
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might vitiate the treatment of a headache but not the management of 
rheumatoid arthritis where multiple doses are given to achieve a 
relatively constant plasma level*
Modification of gastric function
Prescott (1974) reviewed the mechanisms of drug absorption 
interactions and highlighted the part played by the stomach* It is not 
of itself an important site of drug absorption, but the rate of gastric 
emptying may limit the rate of absorption from the upper small 
intestine. This is important in the context of interactions as the 
rate of gastric emptying can be influenced by many drugs, e.g. 
anticholinergics, antihistamines, tricyclic antidepressants, narcotic 
analgesics and metoclopramide. This was clearly demonstrated by 
Nimmo et al (1973) who studied the effect of propantheline and 
metoclopramide on the absorption of the weak acid paracetamol, whose 
rate of absorption in man had been shown to be directly related to the 
rate of gastric emptying (Heading et al 1973 )• Propantheline and 
metoclopramide were known to delay and accelerate gastric emptying 
respectively and would therefore illustrate pharmacological interference 
with gastro-intestinal function resulting in drug interactions.
Figure 25 (right hand graph) shows that gastric emptying was 
prolonged by propantheline, (six convalescent hospital patients) with 
a significant reduction in the rate of paracetamol absorption, peak 
plasma paracetamol concentration and the time taken to reach the peak. 
There was also a reduction in the 0-12 hour urinary excretion of total 
unchanged and conjugated paracetamol but the total amount excreted in 
24hours was unchanged. Thus, propantheline delayed gastric emptying 
and reduced the rate of paracetamol absorption but did not reduce the 
total amount absorbed, (of* analogue computer simulation, Hgure 22).
PARACETAMOL ALONE
£
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Z
PROPANTHELINE
HOURS AFTER ADMINISTRATION
2.0
2 I O
p a r a c e t a m o l
HOURS AFTER ADMINISTRATION
FIGURE 25 Effects of propantheline (right) and metoclopramide (left) on 
paracetamol absorption in six patients and five healthy 
volunteers respectively.
From Kimmo et al 1973 > by kind permission of the authors and 
the Editor of the British Medical Journal,
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FIGURE 26 The effect of propantheline and metoclopramide on paracetamol 
absorption in a single subject. From Uimmo et al 1973} 
by permission as in Figure 25*
The opposite effect was shown by metoclopramide, Hgure 25 (left' 
hand graph) which significantly increased the rate of paracetamol 
absorption. The mean maximum plasma concentration (five volunteers) 
was increased and the mean time to peak concentration decreased (cf. 
analogue computer simulation, Hgure 22). Hgure 26 shows that these 
observations could be repeated in the same individual*
These experiments were designed to show the effect of modified 
gastric motor function on drug absorption. The dose, timing of 
administration, and duration of action of the drugs concerned were 
factors which were of crucial importance in determining the outcome. 
Lengthening the time interval between the administration of paracetamol 
and propantheline or metoclopramide would undoubtedly reduce and 
finally abolish the effects on paracetamol absorption. This, of 
course, reinforces the point that drug interactions may often be 
avoided by intelligent adjustment of dose and/or timing interval.
Atropine and metoclopramide were used in similar studies by 
Gothoni et al (1972) to show, respectively, delayed and accelerated 
absorption of pivampicillin and tetracycline. But Manninen et al 
(1973) obtained paradoxical effects with digoxin. In patients on 
maintenance digoxin therapy, propantheline increased serum digoxin 
concentrations while metoclopramide lowered them. !ttie results with 
propantheline were confirmed in healthy volunteers taking digoxin 
tablets, but absorption of digoxin in liquid form was unaffected by 
propantheline (Hgure 27)*
The discrepancies in the results obtained by these workers could 
probably be explained on the basis of the dissolution characteristics 
and absorption properties of digoxin. "When ingested in tablet form, 
disintegration, dissolution and absorption in the upper gastro-intestinal 
tract determine the bioavailability of digoxin. Rapid gastro-intestinal 
transit induced by metoclopramide could reduce the effective time for
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dissolution and absorption whereas propantheline would have the opposite 
effect by lengthening the effective absorption time.
A number of other studies have attested to the effects of drug- 
induced alterations of gastro-intestinal function on drug absorption. 
Levy, Gibaldi and Erocknal (1972) showed that propantheline delayed the 
absorption of riboflavin, but greatly increased the total amount 
absorbed. Adjepon-Yamoah, Scott and Prescott (1973) observed a marked 
delay in the absorption of orally administered lignocaine in patients 
premedicated with atropine prior to laparoscopy and Consolo et al (1970) 
demonstrated that desmethylimipramine delayed the absorption of 
phenylbutazone•
Absorption of drugs from the gastro-intestinal tract is clearly a 
complex process. The rate of gastric emptying may often be an important 
rate-limiting step, and may itself be determined by pharmacological 
factors. This, together with more generalised changes in gastro­
intestinal motility and peristalsis, may modify tablet disintegration 
and dissolution and increase or decrease the contact time between drug 
and absorptive mucosa.
4.3. INTERACTIONS IN THE PHARMACOKINETIC PHASE
The basic factors affecting transit to and from receptor sites 
which can be altered by drug interactions can be summarised as follows s
(a) Factors affecting transit of active drug to site of action
i. Rate and extent of absorption of drug (discussed under 
•'Interactions in the pharmaceutical phase'*)
ii. Distribution of active drug from plasma to tissues and 
site of action.
iii. Metabolism of inactive drug to biologically active 
metabolites.
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(b) Factors affecting removal of active drug from site of action
i. Redistribution from site of action to other tissues.
ii. Metabolism of active drug to inactive metabolites,
iii. Excretion of drug and metabolites, principally in the 
urine and bile*
A schematic representation of these mechanisms is shown in Hgure 28. 
The pharmacokinetic components which may be modified by drug interactions 
are therefore:
1. Distribution 
2* Metabolism 
3* Excretion#
4*3*1# Redistributional interactions
Drugs are present in the plasma in two forms - free and protein 
bound. Transfer across cell membranes can only be achieved by the 
free drug, which is therefore regarded as the pharmacologically active 
component* Binding occurs principally to albumin and is easily 
reversible. Drug molecules associated with albumin will be readily 
liberated as the free concentration in the plasma declines*
Reversibility and lack of specificity of binding enable plasma albumin 
to act as a transport organ designed to regulate the distribution of 
the majority of drugs throughout the body. Many acidic drugs share 
the same limited number of binding sites on plasma albumin and can 
displace one another under certain conditions. The increased 
concentration of free drug may then lead to enhanced drug effects and 
toxicity*
Drugs may interact at plasma protein binding sites by competitive 
and non-competitive mechanisms, the latter probably being due to 
configurational changes in the protein molecule (O'Reilly and Aggeler,
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1970; Levy 1970). The chemical structure of drugs cannot predict 
whether or not they are likely to participate in such interactions, 
but when they do, important changes in drug effects will only occur 
with drugs which are normally highly bound to plasma protein ( ^ 90$), 
since even a small change in binding will then have a disproportionate 
effect on the concentration of unbound drug.
Distribution model
Basselblatt (1972) has proposed a simple model to illustrate the 
relationship between the degree of binding of a drug and its distribution 
and this can be used to visualise the effects of displacement 
interactions. The model assumes that drug molecules which are not 
bound to plasma proteins are in equilibrium with drug molecules freely 
distributed throughout the whole of the body water. They will then 
leave the blood and enter a space thirteen times as large as the plasma 
volume (Figure 29)* If, for example, 70$ of a drug within the blood 
is bound, 85$ of the total amount of drug present in the body at 
equilibrium will be free. On the other hand if a drug is 98$ bound, 
only 22$ of the total amount will be free. This relationship between 
bound drug and the distribution of free drug at equilibrium can be 
computed over a wide range of theoretical binding values and the results 
expressed graphically as in Hgure 30. The shape of the curve clearly 
illustrates that in this model system, redistribution of a drug is only 
likely to be of significance when initial binding values are high ( ^ 90$). 
Figure 31 examines two portions of this curve in detail. Typically, 
a change of binding from 98$ to 95$ would be associated with an 18.8$ 
rise in the free content of drug, whereas even a relatively large change 
at a lower level, e.g. 30$ to 20$, would lead to no significant change 
in distribution (approximately 1$). This would apply to a drug such
42 LD
■FIGURE 29 Distribution model showing the relationship between the protein 
binding of drugs in the plasma and distribution of free drug 
in the extravascular fluid space, (plasma volume = 3L; whole 
body water volume = 42L). Assumptions made : binding occurs
only on plasma proteins, free drug molecules are distributed 
throughout the body water space. D is free, active drug and 
PD is drug reversibly bound to plasma proteins.
Redrawn from Hasselblatt 1972, by kind permission of the author 
and Excerpta Medica.
PROTEIN BINDING 
AND 
DISTRIBUTION
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FIGURE 30 Graphical representation of the relationship between
the plasma protein binding of a drug and its distribution 
throughout the extravascular fluid space.
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.FIGURE 31 The effect of protein binding displacement on the distribution 
of drugs. Two portions of the curve shown in Figure 30 are 
examined : L.H. scale and curve for binding values in the 
90-100$ range and R.H. scale and '’curve” for binding values 
in the 20-30$ range.
See text for further details.
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as digoxin with binding values of 30-40$ at therapeutic concentrations 
(Wallace and Whiting 1974)* It is relatively easy to demonstrate 
changes like this in the test tube with human plasma, but this should 
constitute only the first rudimentary step in the evaluation of 
displacement phenomena#
Warfarin-phenylbutazone interaction
Much emphasis was formerly placed on the interaction between 
warfarin and phenylbutazone at plasma protein binding sites (Aggeler 
et al 1967) and warfarin displacement with a rise in free concentration 
could be readily demonstrated by such in vitro techniques as 
ultrafiltration (Solomon and Schrogie 1967)# The present author 
set up a comparable system using Sephadex Gel filtration and was able 
to demonstrate the displacement of "^0-warfarin from albumin by 
phenylbutazone (Figure 32, author's unpublished observations)#
Sephadex gel filtration separates substances in solution according 
to their size and molecular weight. The relationship between the size 
of, e.g# drug molecules and the interstices of the gel set up in a 
vertical column determines the rate at which the drug molecules 
gravitate down the column. Fractionation can be achieved by collecting 
the effluent from the column over a period of time. Substances of 
relatively high molecular weight gravitate first while lighter molecules 
tend to be retained# Figure 32 shows that warfarin is almost totally 
associated with the protein (albumin) fraction in plasma (left hand 
upper and lower graphs) but when phenylbutazone is added, a proportion 
of the warfarin is displaced and retained to appear later as free drug 
(right hand upper and lower graphs). The relevance of these observations 
to the clinical situation, however, must be examined.
Whrdell (1974)* in his critical review of putative clinical examples
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of redistributional drug interactions, stresses a number of criteria 
which should be applied to the analysis of such interactions. In 
vitro experiments should be followed by a demonstration that 
redistribution actually occurs in human subjects. Plasma samples 
should be assayed for both total and free concentrations of displaced 
drug and should show a fall in total concentrations consistent with a 
fall in bound drug partially offset by a rise in the free concentration.
A quantitative assessment of the overall pharmacokinetic changes should 
be made to see whether redistribution alone can wholly account for the 
changes or whether other mechanisms need to be invoked, Qlie transient 
nature of many in vivo binding interactions underlines the complex 
dynamic processes with which they may be associated, e.g, alterations 
in drug metabolism and elimination, Ihus the demonstration of warfarin 
displacement by phenylbutazone is now known to be only one component of 
the interaction between these two drugs.
A consideration of the stereochemical configuration of warfarin 
led to findings which indicated a much more subtle and complex interaction 
than had been previously supposed (Lewis et al 1974)* V&rfarin was 
known to exist in two isomeric forms, (R)(+)Warfarin (R Warfarin) and 
(S)(«)warfarin (S Warfarin), the clinically available formulation being 
a mixture of equal parts of these isomers (a racemate). An examination 
of the metabolic fate of each isomer (Lewis and Ttager 1971) revealed that 
they were metabolised by different routes, and previous work had 
demonstrated that S Warfarin was five times more potent as an 
anticoagulant than the R isomer, both in man (O’Reilly 1971) and. the rat 
(Elbe, West and Link 1966; Breckenridge and Orme 1972). Ihis meant 
that the configuration of warfarin would greatly influence its 
pharmacological effect. Moreover, the metabolic fate of each isomer 
might show different susceptibilities to the influence of other drugs, 
suggesting that interactions with warfarin might be manifest
43
stereospecifically* Lewis et al (1974) reported a reduction in the 
plasma clearance of S Warfarin and an increase in the plasma clearance 
of the R isomer after phenylbutazone* The rate of clearance of the 
racemic mixture, however, was unaffected as the depressed S isomer 
clearance was effectively masked by the stimulated clearance of the 
R isomer (Eigure 33)• The impaired metabolism of the more potent 
S Warfarin, therefore, provided evidence of another important 
mechanism by which phenylbutazone augments warfarin induced anticoagulation.
General considerations
A great number of drugs have been implicated in protein 
displacement interactions notably acidic compounds such as non-steroid 
anti-inflammatory agents including aspirin, uricosuric drugs, 
sulphonamides, penicillins, nalidixic acid, oral anticoagulants, 
clofibrate, methotrexate, sulphonylureas, diazoxide, ethacrynic acid, 
barbiturates, phenytoin and trichloracetic acid* Many in vitro studies 
attest to protein displacement interactions with these drugs, but the 
evidence for a redistributional mechanism in man is less secure* As 
with the phenylbutazone-warfarin interaction, initial enthusiasm for 
protein binding displacement to explain the potentiation of tolbutamide 
induced hypoglycaemia by phenylbutazone or sulphaphenazole has been 
tempered by subsequent work which demonstrated inhibition of tolbutamide 
metabolism (Christensen et al 1963)*
Strong circumstantial evidence however has been presented for a 
redistributional mechanism as being partly responsible for warfarin 
potentiation by chloral hydrate - or more accurately by its major 
metabolite, trichloracetic acid. Sellers and Koch-Weser (1970) showed 
that trichloracetic acid accumulated during chloral hydrate therapy, 
displaced warfarin from its binding sites, and caused a fall in the
R elimination
I+"
PHENYLBUTAZONE
S
elimination
FIGURE 33 Schematic representation of the phenylbutazone-warfarin 
interaction. Elimination of R-warfarin is increased and 
that of S-warfarin decreased by phenylbutazone.
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.total plasma concentration of warfarin. An associated increase in 
prothrombin time reflected the greater amounts of warfarin available 
at receptor sites and the increased distribution also made more 
warfarin available for metabolism and so reduced its half-life.
The dynamic nature of these changes - the liberation of an excess 
amount of pharmacologically active drug on the one hand and its increased 
metabolism on the other - re-emphasises the transient nature of these 
interactions, but as Sellers and Koch-^ser (1971) have pointed out, 
there is sufficient potentiation of warfarin activity for the interaction 
to be of clinical significance. Of 52 hospitalised patients who 
received warfarin and chloral hydrate concomitantly, 13 showed significant 
potentiation of anticoagulation. It is interesting to note, however, 
that in a much smaller series of five patients taking warfarin and 
chloral hydrate, Breckenridge et al (1971), although they demonstrated 
a fall in plasma warfarin concentration failed to detect any commensurate 
changes in anticoagulation. Thus the relationship between redistribution 
and detectable changes in pharmacological activity can be somewhat 
tenuous.
lUrther understanding of these interactions will depend on the 
application of more rigorous criteria. Any displacement that occurs 
will always invalidate concentration-effect relationships based on the 
measurement of total plasma concentrations, and this problem could be 
overcome by the routine measurement of free drug concentrations in 
plasma ultrafiltrates.
4.3.2, Personal observations :
PLASMA DRUG BINDING IN ELDERLY PATIENTS
Many protein binding studies, especially those carried out 
exclusively in vitro, have failed to relate experimental findings to 
the clinical situation. One particular problem which seemed to demand 
a combined clinical and experimental approach was the increased 
susceptibility to drug toxicity in the elderly (Hurwitz 1969)* This 
signified that ageing may be associated with some alteration in drug 
handling. Convincing evidence of this was lacking until O'Malley et al 
(1971) found that the half-lives of antipyrine and phenylbutazone were 
prolonged in a group of elderly patients. Evidence has also been 
presented for increased phenytoin clearance in an elderly group (Bayes 
et al 1975b) which correlated inversely with reductions in both plasma 
phenytoin binding and albumin levels. Reduced albumin levels were also 
thought to contribute to reduced warfarin binding in the elderly (Hayes 
et al 1975a)» It was therefore of interest to study the various factors 
which may be responsible for changes in protein binding in the elderly 
and assess the contribution made by both decreased albumin levels and 
multiple drug therapy (Wallace, Whiting and Runcie 1976)•
Patients and methods
Sixty nine subjects were studied, divided into the following groups:
(a) Sixteen healthy volunteers, aged 19-40 years (mean 27 years) 
taking no drugs. (Group A)
(b) Fifteen surgical and gynaecological patients, aged 14-39 years
(mean 30 years), not acutely ill but taking sedatives,
analgesics and a variety of other drugs, including antibiotics, 
(Group B)
(c) Sixteen elderly patients, aged 69-85 years (mean 79 years) 
taking no drugs. (Group C)
(d) Twenty two elderly patients, aged 74-92 years (mean 84 years) 
taking one or more drugs at the time of the study# (Group D)
Blood samples (10 ml) were withdrawn from hospital patients
approximately two hours after the first morning drug administration
round, and collected into tubes containing lithium-heparin as
anticoagulant. Plasma was immediately separated by centrifugation,
an aliquot reserved for routine biochemical tests, including serum
proteins, and the rest was stored at -20°C until use.
Aliquots of plasma (l ml) from each subject were incubated for
30 minutes at room temperature with three "test" drugs - salicylic
acid (280-400 ^ ig/ml) sulphadiazine (300-500 ^ ig/ml) and phenylbutazone
(75-200 ^ lg/ml)# The plasma was then subjected to ultrafiltration
(Amicon Centriflo membrane cones or the Amicon Multi-Micro
Ultrafiltration System) and samples of the original plasma-drug solution
and ultrafiltrate were analysed for total and free drug respectively#
Salicylate was determined by the method of Trinder (1953 )\
2
sulphadiazine by the method of Bratton and Marshall (1939) and
q
phenylbutazone by the method of Andreason (1973) •
1. Trinder, P. (1953) Rapid determination of salicylate
in biological fluids. Biochemical Journal. 57> 301-303.
2. Bratton, A.C. and Marshall, E.K. (1939) A new coupling
component for sulphanilamide determination. Journal of Biological 
Chemistry. 128, 537-550.
3* Andreason, F. (1973) Ptrotein binding of drugs in
plasma from patients with acute renal failure. Acta Pharmacologica 
et Toxicologica. 32, 417-429*
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A separate series of experiments was performed to determine the 
effect of plasma dilution on the binding of the three test drugs.
Serial dilutions of 1:5> 1:20 and 1:100 were made of normal plasma 
using Sorensen's phosphate buffer (pH 7»4)« The three drugs were 
added as described above, the samples ultrafiltered, and total and 
free concentrations measured as before.
Results
Figure 34 shows the relative amounts of free drug in the plasma 
of all subjects. Significant increases in free salicylate, sulphadiazine 
and phenylbutazone were found in elderly patients taking drugs (Group D) 
when compared with Group A. A similar increase in free phenylbutazone 
was seen in young hospital patients and elderly patients not on drug 
therapy (Groups B and C),
Elderly subjects showed a significant reduction in plasma albumin 
levels (p <0,001 for Groups C and I) compared with Groups A and 
Figure 35).
Bhe effect of in vitro plasma dilution on the binding of all three 
drugs is shown in Figure 36. Ihe binding of phenylbutazone decreased 
dramatically with increasing dilution but for both salicylate and 
sulphadiazine a considerable reduction in plasma protein concentration 
was necessary before any real increase in unbound drug occurred.
Figure 37 shows that a highly significant increase in free salicylate 
concentration (p <0.001) was detected in the plasma of elderly patients 
taking two or more drugs. A similar result was observed with 
sulphadiazine.
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Discussion
The changes in plasma protein concentration with age noted in 
this study agreed with previous findings (Woodford-Williams et al 1964)* 
The pattern generally found has been a fall in albumin and a rise in 
gammaglobulin levels, seemingly related to decreased mobility in 
elderly people (Woodford-Williams et al 1964)* This reduction in 
albumin could lead to altered drug distribution characteristics.
This study demonstrated a significant reduction in the plasma 
protein binding of phenylbutazone in the elderly and the plasma dilution 
experiments indicated that phenylbutazone binding - normally about 9Qfo - 
is particularly susceptible to changes in albumin concentration.
Neither of the two less extensively bound drugs, salicylate and 
sulphadiazine showed significant reductions in binding in elderly 
patients not receiving drugs and plasma dilution curves indicated that 
changes in albumin levels did not have such a pronounced effect on the 
binding of these drugs.
The relationship between plasma albumin concentration and competitive 
binding effects has received relatively little attention, but Anton and 
Corey (1971) showed that competition may be enhanced when the plasma 
albumin concentration is reduced. Our findings were related to both 
young and elderly patients, with significantly different albumin levels, 
receiving a variety of drugs. Binding of salicylate, sulphadiazine and 
phenylbutazone was significantly lower in elderly patients receiving 
drug therapy compared to normal healthy young adults, and also to 
elderly drug free subjects. Only phenylbutazone binding was 
significantly reduced in young hospitalised patients receiving drugs, 
and the mean albumin level of this group did not differ significantly 
from that of healthy young adults.
It appears, therefore, that the combination of low albumin levels
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and multiple drug therapy may be responsible for the observed reduction 
in binding of the three test drugs in the elderly group receiving drug 
therapy# It is also apparent that low albumin levels per se can cause 
significant increases in the free concentration of phenylbutazone and 
other highly bound drugs#
The group of young patients receiving drugs had albumin levels 
within the normal range and only phenylbutazone binding was significantly 
reduced# It is probable that the relatively high (normal) albumin 
concentrations encountered in this group reduced the susceptibility to 
competitive effects.
Evidence of the tenuous nature of the relationship between altered 
drug distribution and pharmacological effect has already been presented 
in this thesis# The data presented here could not be analysed 
directly in terms of altered pharmacological effect, but provided 
additional evidence for altered drug handling in the elderly.
It is difficult to say whether or not this would make a significant 
contribution to the increased susceptibility to drug toxicity which 
has been shown to occur in the elderly, but it is certainly important 
to recognise that protein binding relationships alter with age and 
possibly modify the redistributional effects of a protein binding 
interaction. In these circumstances, it would be sensible to exercise 
particular caution when a combination of highly bound drugs was being 
used. It might even be advisable to test each individual’s plasma for 
its ability to bind the drugs in question.
No definite relationship between the type of drug taken by elderly 
patients in Group D and the observed effects on protein binding could 
be demonstrated. The drugs included hypnotics, tranquillisers, iron 
preparations, analgesics and antibiotics.
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4»3«3* Interactions affecting drag metabolism.
The excretion of many drugs by the kidney is limited by their 
lipid solubility and would proceed at a very slow rate if the liver 
had no capacity to convert lipid soluble drugs into more water soluble, 
polar compounds, Fortunately, the smooth endoplasmic reticulum in 
liver cells contains enzymes which can effect this conversion by a 
variety of oxidative, reductive, and conjugation mechanisms including 
hydroxylation, dealkylation, deacetylation and glucuronidation (Brodie, 
Gillette and La Du 1958)* Eh® polar metabolites which are formed are 
usually less toxic than the parent compound because their reduced 
lipid solubility precludes transfer across cell membranes to potential 
sites of action. Occasionally, however, despite increased polarity, 
a derived product may gain pharmacological activity which is not present 
in the parent compound if the conversion unmasks or produces a new 
functional group.
Many chemicals and lipid soluble drugs can increase the rate of 
their own metabolism and the metabolism of other pharmacologically and 
chemically unrelated compounds by inducing an increase in the size and 
enzyme content of the smooth endoplasmic reticulum. This non-specific 
phenomenon has been observed in many mammalian species and can be viewed 
as an adaptive process which protects the organism against the effects 
of excessive amounts of foreign compounds (Remmer 19&4* 19^7» 1972; 
Conney 19^7; Conney and Bums 1962), In therapeutic terms, induction 
of drug metabolism by one drug may increase the rate of metabolism of 
other drugs, thereby reducing their therapeutic and toxic effects. The 
original response may be regained by an increase in dose but this may 
lead to a problem when the inducing drug is withdrawn. Metabolism 
then returns to normal with the risk of an exaggerated response or 
toxicity if the dose is not reduced.
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The activity of drug-metabolising enzymes can also be inhibited 
by certain compounds, which presents the opportunity for mutual 
inhibition of metabolic inactivation. Thus one drug may inhibit the 
metabolism of another and cause cumulation and toxicity.
Two basic mechanisms, therefore, may underlie interactions 
affecting drug metabolism - (a) enz2/me induction, and (b) enzyme
inhibition*
Enzyme induction
The number of drugs which can significantly induce drug metabolism 
during therapy is relatively small and includes phenobarbitone, the 
most widely recognised example, other barbiturates, phenytoin, 
carbamazepine, meprobamate, glutethimide and alcohol.
Individuals differ in their response to inducing agents because 
the degree of induction is under genetic control (Vessell and Page 1969), 
Some people have no alteration in drug metabolism; others have striking 
effects* Unfortunately, it is difficult to predict the response of an 
individual to enzyme induction, although in general, the greatest effect 
is seen in persons who initially show the slowest metabolism (Nies 1974)* 
Interactions involving enzyme inducers, therefore, may or may not reach 
clinical significance but their foreknowledge should facilitate dosage 
adjustments to maintain a desired effect.
The drug which has been investigated most extensively in this 
regard is warfarin, whose metabolism can be increased and effects 
diminished by inducing agents (Levy et al 1970; Breckenridge et al 
1971» Koch-Weser and Sellers 1971 )• As accurate control of 
anticoagulation is essential, any acceleration of metabolic inactivation 
of warfarin has important therapeutic consequences. The daily dose 
required for adequate suppression of prothrombin-complex synthesis
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is increased and necessitates careful adjustment if loss of adequate 
therapeutic effect is to be avoided* The exact dosage increase 
required to balance the induction effect varies greatly and is 
unpredictable, but may exceed 100 per cent* JUrthermore, it is very
difficult to achieve stable anticoagulation in the presence of enzyme 
inducers, particularly hypnotics and alcohol which'patients may take 
in a somewhat erratic fashion* Finally, withdrawal of the inducing 
agent may cause bleeding from excessive hypoprothrombinaemia if 
appropriate reduction of warfarin maintenance dose is not anticipated.
Unlike digoxin, which is excreted largely unchanged in the urine, 
digitoxin undergoes extensive metabolism and Solomon and Abrams (1972) 
showed that steady-state levels of digitoxin in the plasma could be 
lowered by phenylbutazone and phenytoin, both acting as inducing 
agents. Discontinuation of these drugs resulted in a return of 
plasma digitoxin levels to control values.
Rifampicin and oral contraceptives
Another interesting and important example of the consequences 
of enzyme induction was provided by Reimers and Jezek (1971) when they 
reported that simultaneous administration of rifampicin and oral 
contraceptives resulted in an increased incidence of "spotting" and 
breakthrough bleeding. Rifampicin, introduced relatively recently 
for the treatment of tuberculosis, was subsequently shown to be a 
potent enzyme inducer (Remmer, Schoene and Eleischmann 1973) and a 
further study by Nocke-Iinck, Breuer and Reimers (1973) showed that 
five pregnancies occurred in 88 rifampicin-treated women receiving 
oral contraceptives. These clinical observations, combined with a 
study of urinary oestrogen excretion, suggested that rifampicin may 
cause partial or total failure of oral contraceptive therapy by
altering the biogenesis and/or inducing the metabolism of oestrogens.*
Bolt, Kappus and Bolt (1975) have recently clarified the position by 
demonstrating a four-fold increase in the hydroxylation of 
ethinyloestradiol and oestradiol by human liver microsomes in vitro 
after only several days of rifampicin treatment. These authors were 
satisfied that the in vitro findings could be extrapolated to the in 
vivo situation because hydroxylation constituted the only metabolic 
route of quantitative significance for the oxidative inactivation of 
ethinyloestradiol. Moreover, the oral effectiveness of ethinyloestradiol 
depended on its relatively slow rate of inactivation when compared with 
oestradiol, known to be ineffective when given by mouth (Reed, Fotherby 
and Steele 1972; Fotherby 1973)* The results presented by Bolt et al 
(1975) indicated that induction by rifampicin would shift the half- 
life of ethinyloestradiol towards that of oestradiol, thus rendering 
oral ethinyloestradiol ineffective* The wisdom of low dose oestrogen 
oral contraceptive therapy cannot now be disputed but women on rifampicin 
obviously deserve special consideration. Rxture clinical surveys 
should determine whether higher doses of oestrogen are required to 
maintain effective oestrogen activity.
Rifampicin and anticonvulsants
A problem encountered recently also illustrated the induction 
properties of rifampicin. A man of 36 with epilepsy, normally well 
controlled on the combination of phenobarbitone, ethosuximide and 
phenytoin, developed frequent major fits soon after starting rifampicin 
therapy for tuberculosis* Measurement of the serum steady-state 
phenytoin concentration by radioimmunoassay revealed a level of 0*9 pg/ml, 
well below the accepted therapeutic range of 10-20 ^ ig/ml* This raised 
the possibility of induction of phenytoin metabolism from the combined
induction effects of phenobarbitone and rifampicin as phenobarbitone 
itself is known to reduce phenytoin levels (Morselli, Rizzo and 
Garattini 1971)* The introduction of rifampicin probably 
exaggerated this effect. It was important to obtain evidence of 
microsomal enzyme induction and this was provided by measurement of 
the plasma antipyrine half-life. Antipyrine is suitable for this 
purpose since it is almost completely metabolised in the liver (Brodie 
and Axelrod 1950) and is not bound to plasma proteins (Soberman et al 
1949)* The rate of antipyrine metabolism in man has been shown to 
be under genetic control (Vessell and Page 1968a) and to increase 
with exposure to drugs (Vessell and Page 1969)# The half-life is 
measured by giving a standard oral dose (18 mg per Kg) in aqueous 
solution and assessing the decline in antipyrine concentration, 
measured by the method of Brodie et al (1949)» over a period of 24 
hours in either plasma or mixed saliva samples.
The patient's antipyrine half-life was 5*17 hours, compared 
with 12.4 ± 2.04 (S.D) hours in a group of normal control subjects.
This highly significant shortening of the anitpyrine half-life, 
therefore, provided good evidence of microsomal enzyme induction. 
Gradual increase in the daily dose of phenytoin over a period of four 
weeks produced a therapeutic level of 11 ^ ig/ml with resolution of the 
fits. This, of course, stressed the importance of anticipating 
careful reduction of phenytoin dosage on completion of rifampicin 
therapy to avoid phenytoin intoxication.
Induction and toxicity
Instead of reducing the therapeutic effect of a drug, the 
administration of an inducing agent may have the opposite effect and 
lead to increased toxicity. Relatively few clinical examples are
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known but this type of interaction is potentially of great significance. 
The formation of active intermediary metabolites has been considered 
to be one of the mechanisms by which a number of experimental drug 
toxicity reactions have occurred. For example, the hepatoxicity of 
carbon tetrachloride can be increased by pre-treatment of animals with 
inducing agents such as phenobarbitone or D.D.T., and protection against 
hepatic necrosis can be achieved by inhibition of carbon tetrachloride 
metabolism by hypothermia, anti-oxidants, the inhibiting drug SKF 525-A 
or a previous small dose of carbon tetrachloride itself (Marchand,
McLean and Plaa 1970; Glende 1972). Inducers have also been implicated 
in carcinogenesis. Prescott (1970, 1973) suggested that the renal 
pelvic tumours observed in analgesic abusers with renal papillary 
necrosis were caused by carcinogenic hydroxamino metabolites resulting 
from induction of phenacetin metabolism by concurrently administered 
antipyrine. Since so many drugs, dietary constituents and environmental 
chemicals are known to be inducing agents, potentiation of drug toxicity 
and carcinogenesis caused by microsomal enzyme induction may assume 
considerable importance•
Enzyme inhibition
Several drugs have been shown to inhibit the metabolism of other 
drugs in man with important clinical consequences. In contrast to 
the genetic variability of enzyme induction, enzyme inhibition seems to 
be less affected by genetic differences and will probably occur in all 
patients given certain combinations (Nies 1974)* Microsomal enzymes 
may be involved but other enzymes which inactivate drugs may also be 
inhibited. Allopurinol, chloramphenicol, dicoumarol, disulfiram, 
isoniazid, methylphenidate, monoamine oxidase inhibitors, phenyramidol 
and sulphaphenazole all inhibit the metabolism of several drugs, notably
coumarin anticoagulants, phenytoin and tolbutamide# Such interactions 
have declared themselves relatively easily because of the low 
therapeutic ratio of the inhibited drugs and their obvious toxic 
manifestations.
Sulthiame and phenytoin
The introduction of sulthiame in the treatment of focal or major 
epilepsy was soon followed by reports of an intoxication syndrome 
similar to that produced by phenytoin (La Veck, de la Cruz and Thomas 
19^2; Ingram and Ratcliffe 19^3; Gordon 1964) closer examination 
of these reports revealed that in fact the syndrome was always 
associated with the combination of sulthiame and phenytoin# Hansen, 
Kristensen and Skovsted (1968) showed that sulthiame caused an 
elevation of the serum concentration of phenytoin and suggested that 
the metabolism of phenytoin by liver microsomal enzymes was inhibited 
because they found a prolongation of the serum half-life following 
addition of sulthiame to the patients’ treatment# These results have 
been confirmed more recently in a series of studies by Houghton and 
Richens (1973> 1974a and 1974"b) when they showed unequivocally that 
sulthiame or one of its metabolites inhibits the parahydroxylation of 
phenytoin by hepatic microsomal enzymes#
Thus, despite the fact that phenytoin is an excellent drug in the 
treatment of epilepsy, interaction with other anticonvulsants, e.g# 
phenobarbitone and sulthiame, may leave many patients without the full 
benefits of treatment# The availability of plasma level measurements 
of phenytoin should make it possible to tailor and adjust dosage 
regimens for individual patients so that therapeutic efficacy can be 
maximised and the risk of adverse effects from interactions minimised# 
But although the range of therapeutically effective concentrations of
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phenytoin has been established (Kutt and McDowell 1968), this may not 
be entirely relevant to the common practice of treating patients with 
combinations of several anticonvulsants. Knowledge of this range does, 
however, identify plasma concentrations which are associated with 
toxicity.
4.3.4. Personal observations
EFFECT OF ACUTE ALCOHOL INTOXICATION 
OH THE METABOLISM AND PLASMA KINETICS 
OF CHLOBDIA ZEPOXIDE^
Enzyme inhibition may be related to the length of exposure to a 
drug. Many inducing agents cause an initial inhibition followed by 
stimulation. Acute ethanol intoxication, for example, is associated 
with impairment of pentobarbitone and meprobamate metabolism (Rubin 
et al 1970) whereas drug metabolism is accelerated in chronic alcoholics 
(Kater et al 1969). As it is common practice to use relatively large 
doses of the benzodiazepine chlordiazepoxide in the suppression of 
delirium tremens in acute ethanol intoxication, it seemed pertinent to 
investigate the effect of acute alcoholism on the metabolism of this 
drug.
Patients and methods
In a relatively small, preliminary study, two groups of subjects 
have been studiedj
(a) Three healthy male volunteers, and
(b) Pour adult male patients admitted to the Psychiatric 
Department of Stobhill General Hospital, Glasgow, with 
a diagnosis of acute alcohol intoxication.
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The volunteers were given a single oral dose of 25 mg 
chlordiazepoxide and 10 ml blood were withdrawn into lithium-heparin 
anticoagulant at the following tinesj pre-dose (control) and ^ , 1, 2,
4, 6, 8, 12 and 24 hours after the dose. Plasma was separated by 
centrifugation and stored at ~20°C until required for analysis of 
chlordiazepoxide and its desmethyl metabolite by high pressure liquid 
chromatography (H.P.L.C) (Skellem, Meier and Whiting 1976).
Once it had been established that chlordiazepoxide would be 
appropriate in the management of the alcoholic patients, informed 
consent was obtained for the study, a control blood sample was 
withdrawn, the first dose administered, and samples then taken at the 
following times; 1, 2, 3, 4» 5 and 6 hours after the first dose, then 
once daily for 4-5 days, immediately prior to the second morning dose. 
Plasma was separated, stored at -20°C and subsequently analysed as 
indicated above* An aliquot of the control sample was also reserved 
for routine biochemical assessment of liver function. A careful record 
was made of the time of administration and amount of each dose, and the 
precise times of each blood sample. The daily dose of chlordiazepoxide 
during the study period ranged from initial high doses of 200 mg to 
lower doses of 30 mg given in three or four equally divided doses.
Evaluation of the data
For all subjects the disposition kinetics of chlordiazepoxide 
after oral dosing could be described by a one-compartment open model 
(Figure 38) with metabolic conversion of chlordiazepoxide to its 
desmethyl metabolite and subsequent renal elimination and/or further 
metabolism of both parent drug and metabolite. Pharmacokinetic 
parameters were obtained by digital computation using SAAM (Berman 
and Weiss 1968) a non-linear regression analysis programme.
Ka Ke(D)
K e(M )
GUT
PLASMA
(D)
PLASMA (D) “ CHLORDIAZEPOXIDE in plasma 
u/m(D) =urine/further metabolism
PLASMA(M) =DESMETHYL-CHLORDIAZEPOXIDE in plasma 
U /M cm ) =  urine/further metabolism
FIGURE 58 One-compartment model for chlordiazepoxide kinetics,
showing its metabolic conversion to desmethylchlordiazepoxide. 
All rate constants are assumed to be first-order, i,e, 
concentration dependent, K& is the absorption rate constant 
for chlordiazepoxide, Km is the metabolic rate constant 
characterising the conversion of chlordiazepoxide to 
desmethylchlordiazepoxide, Ke(D) and Kq (m ) are overall 
elimination rate constants for chlordiazepoxide and 
desmethylchlordiazepoxide respectively.
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Results
(a) Normal volunteers
Plasma concentration/time curves for chlordiazepoxide and 
desmethylchlordiazepoxide are shown in Figure 39 which also demonstrates 
the closeness of fit between calculated and experimentally derived data. 
The corresponding pharmacokinetic parameters are shown in Table 7•
These results yield a mean chlordiazepoxide elimination half-life of 
6,98 ± 2*51 (S.D) hours and a mean desmethylchlordiazepoxide 
elimination half-life of 13,1 ±2,6 (S.D) hours. Calculated values 
for the rate constants shown in the proposed model are presented in 
Table 8.
(b) Alcoholic patients
A typical example of the effect of multiple dosing on plasma 
concentrations of chlordiazepoxide and desmethylchlordiazepoxide is 
shown in Figure 40, which also illustrates the predicted drug and 
metabolite concentrations in relation to each dose, according to the 
proposed pharmacokinetic model. Figure 41 shows the plasma 
concentrations of chlordiazepoxide in the first five hours of treatment 
following the initial dose of 50 mg. Also included in this figure 
are serial plasma concentrations of alcohol (measured by gas liquid 
chromatography) which decline linearly as expected with a clearance 
rate of 40 mg$ per hour. Table 9 shows the pharmacokinetic parameters 
of the patients studied. The mean chlordiazepoxide elimination half- 
life was 13*0 ± 3*0 (S.T) hours and the mean desmethylchlordiazepoxide 
elimination half-life was 15.2 ± 6,5 (S.D) hours. Corresponding rate 
constants are presented in Table 10, On the basis of the routine
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FIGURE 39 Observed and predicted plasma levels of chlordiazepoxide and 
desmethylchlordiazepoxide in normal volunteers following a 
single oral dose of chlordiazepoxide* (•) and (o) are 
concentrations of drug and metabolite measured by HPLCj 
the continuous lines are concentration/time relationships 
predicted by kinetic analysis based on the model shown in 
Figure 38*
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FIGURE 41 Observed plasma concentrations of chlordiazepoxide 
during the first five hours of treatment of the 
patient shown in Figure 40* Included are serial 
measurements of plasma alcohol concentration which 
decline linearly at a rate of 40 mg$ per hour.
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biochemical tests, none of the patients had any significant degree of 
hepatic impairment#
Discussion
The limited amount of data presented in this preliminary study 
demonstrated the suitability of the one-compartment open model for 
describing' the disposition kinetics of chlordiazepoxide and its 
metabolic conversion to the desmethyl form after oral administration.
The lack of any significant divergence between predicted and measured 
concentrations of drug and metabolite attested to the adequacy of the 
model•
The major elimination pathway for chlordiazepoxide has been shown 
to be almost exclusively biotransformation to desmethylchlordiazepoxide 
(Koechlin et al 1965)# Almost no unchanged chlordiazepoxide is 
excreted in the urine, and this places considerable emphasis on the 
metabolic rate constant, K^ , shown in the model. The decline of 
chlordiazepoxide levels in the plasma therefore depends on this constant 
and any change in chlordiazepoxide metabolism will be reflected by 
changes in this constant# Volunteers who received single doses of 
chlordiazepoxide had a mean value of 0.0894 ± 0.0232 (S.D)h ^ 
compared with a mean value of 0.0523 ± 0.0116 (S.D)h ^ in the alcoholic 
patients. This was reflected by significant differences in the 
elimination half-lives of chlordiazepoxide in the two groups# The 
half-life in the alcoholics (mean 13.0 ± 3.0 (S.D) hours) was 
approximately double that found in the volunteers (mean 6.98 ± 2.51 
(S.D) hours) and this provided good evidence of slower metabolic 
conversion of chlordiazepoxide to desmethylchlordiazepoxide in the 
acutely intoxicated patients.
The range of half-lives observed in this study, 4«33 - 9*33 hours
r J.
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in the control group and 10*1 - 15*8 hours in the alcoholic group 
emphasises a degree of variability which may be genetically controlled*
It is also evident that previously reported half-lives of chlordiazepoxide 
of 20-24 hours (Koechlin and D ’Arconte 1963) were over-estimated as the 
result of an assay procedure which could not distinguish between 
chlordiazepoxide and desmethylchlordiazepoxide* As Figures 39 and 40 
show, the metabolite rises to appreciable levels with time and would 
artificially prolong the measured half-life of the parent drug if it 
could not be identified separately*
The elimination of desmethylchlordiazepoxide, characterised by 
the rate constant K0(m ) in the model, has been shown to involve further 
biotransformation to the metabolite demoxepam (Kaplan et al 1970)*
Thus desmethylchlordiazepoxide is an intermediate in the biotransformation 
of chlordiazepoxide to demoxepam* Ke(M) had similar values in the two 
groups with corresponding mean elimination half-lives of 13*1 ± 2.6 (S.D) 
hours in the volunteers and 15*2 ± 6*5 (S.D) hours in the alcoholics.
It appears, therefore, that alcohol dependent enzyme inhibition is 
confined to the first step in the metabolism of chlordiazepoxide*
These preliminary observations were sufficiently encouraging to 
warrant further study and additional subjects have now been included 
in each group* Further pharmacokinetic analysis will be improved by 
the inclusion of plasma levels of demoxepam measured by H.P.L.C.
From a clinical point of view, the decreased elimination of 
chlordiazepoxide in patients with acute alcohol intoxication does not 
seem to be a disadvantage, but it does demonstrate that enzyme inhibition 
is associated with this condition. Paradoxically, the rate of alcohol 
clearance is increased, in keeping with heavy drinking (Kater, Carulli 
and Iber 1969; Kater et al 1969)* The patient illustrated in Figures 
40 and 41 had an alcohol clearance rate of 40 Per hour, the upper 
limit of normal being 20 mg$ per hour (Forney and Harger 1969)* This
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increase may well represent an adaptive response to excessive amounts 
of alcohol. Despite the relatively high plasma chlordiazepoxide 
concentrations observed and predicted, (cf. peak concentrations in 
volunteers after a single dose and concentrations attained on day 
three in the patient illustrated), drowsiness was not a feature of the 
treatment and the patients remained alert and relatively mobile during 
the day. However, the anxiety and agitation associated with delerium 
tremens was effectively suppressed.
It appears, therefore, that delirium tremens presents a challenge 
to the psychopharmacological effects of relatively high doses of 
chlordiazepoxide in that it over-rides any significant sedative effect 
which the drug would normally exert at much lower plasma concentrations. 
Ibrtunately, the distressing symptoms of anxiety and agitation usually 
respond satisfactorily. The exact relationship between the suppression 
t of delirium tremens and plasma concentrations of chlordiazepoxide and 
its metabolites remains to be determined. By definition, alcohol will 
always play an important part in this relationship.
4.3.5* Interactions affecting renal excretion
Interactions that modify the renal excretion of drugs only assume 
importance when a drug or its active metabolite is excreted largely 
unchanged in the urine. Three mechanisms are responsible for renal 
elimination: glomerular filtration, tubular reabsorption and active
tubular secretion.
Glomerular filtration produces an ultrafiltrate of plasma containing 
free drug molecules and is not significantly affected by other drugs. 
Disease states do, however, modify glomerular filtration (See Chapter 3) 
and its reduction may greatly increase the half-life of some drugs.
Many weak acidic drugs are transported from the tubular capillaries
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across the proximal tubular cell into the tubular urine against a 
concentration gradient by an active process. Biese drugs include 
the penicillins, most anti-inflammatory agents including salicylate, 
phenylbutazone and indomethacin, uricosurics such as probenecid and 
sulphinpyrazone, thiazide diuretics and some oral hypoglycaemics 
including chlorpropamide. In general, the administration of such 
acidic drugs will slow the tubular secretion of other concurrently 
administered acidic drugs. Similarly, the administration of a base 
will slow the tubular secretion of other bases. The effect of 
probenecid on the elimination of penicillin is well known and has been 
exploited therapeutically. Probenecid has also been shown to decrease 
the renal excretion of indomethacin (Skeith, Simkin and Healy 1968;
Brooks et al 1974) with a corresponding rise in indomethacin plasma 
levels. It remains to be determined whether or not this interaction 
could be exploited in the management of rheumatoid arthritis. For 
example, an adequate level of indomethacin maintained throughout the 
night by delay in its elimination might well help to suppress the 
distressing symptoms of morning stiffness.
Adverse interactions based on this competitive mechanism include 
methotrexate toxicity as a result of its delayed excretion by salicylate 
(Liegler et al 1969) and the potentiation of the hypoglycaemic effect of 
acetohexamide by phenylbutazone (lield et al 1967). In the latter case, 
excretion of the active metabolite hydroxyhexamide is delayed but there 
is no effect on the parent compound.
Brug molecules in the tubular fluid are progressively concentrated 
and may be reabsorbed into the blood as the glomerular filtrate passes 
down the nephron.' The extent of this reabsorption depends on a number 
of factors including the lipid solubility of the drug - determined largely 
by its degree of ionisation - and the urine pH. An alkaline urine 
favours the excretion of acidic drugs such as aspirin and phenobarbitone
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while basic drugs such as amitriptyline and quinidine are more readily 
excreted in acid urine (Goldstein, Aronow and Kalman 1969)* Ihe 
manipulation of the pH of the glomerular filtrate and the degree of 
ionisation of a drug can, therefore, significantly influence its rate 
of elimination and this forms the basis of the use of forced alkaline 
diuresis in the management of aspirin and phenobarbitone poisoning 
(Waddell and Butler 1957J Lassen I960; Milne 1965).
4.4* INTERACTIONS IN THE PHARMCOLYNAMIC PHASE
A number of complex mechanisms may be responsible for interactions 
in the pharmacodynamic phase which may involve various types of drug 
antagonism or synergism. These mechanisms include:
(a) competition for the receptor site
(b) synergism at the receptor
(c) alteration of the receptor
(d) alteration of the other components at the site of action
(e) effects on a different biological system which has similar 
or opposite effects leading to augmentation or diminution 
of the overall biological response.
4*4«1* Competition for the receptor site
Many pharmacologically active substances compete for common receptor 
sites, e.g. metabolites and antimetabolites, cholinergic and anticholinergic 
agents, histaminergic agents and antihistamines, beta adrenergic and beta 
adrenergic blocking agents, etc. Competitive antagonism signifies 
that the antagonist has affinity for the sites of action but lacks any 
intrinsic activity. The agonist has both affinity for and intrinsic 
activity on the specific receptors.
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Adverse drug interactions based on competition between drugs at 
receptor sites are relatively rare. As an example, it has been suggested 
that the reduced hypoglycaemic action of the sulphonylureas in the 
presence of thiazide diuretics may be partly due to inhibition of insulin 
secretion from the pancreas by the chemically related thiazides (Goldner, 
Zarowitz and Akgun I96O; Samaan, Dollery and leaser 1963; Hicks et al 
1970; Levine 1970)*
The loss of response to indirectly acting adrenergic agents, which 
release noradrenaline from stores at nerve endings, and to compounds 
which deplete those stores by release of noradrenaline, constitute 
further examples of antagonistic interaction at receptor sites. Typical 
is the interaction between adrenergic neurone blocking antihypertensives 
and tricyclic antidepressants. Leishman, Matthews and Smith (1963) 
suggested that imipramine blocked the action of guanethidine in 
hypertensive patients. This was confirmed by Mitchell, Arias and Oates 
(1967) when they showed that the antihypertensive effect of guanethidine 
was significantly reversed by two tricyclic antidepressants (desipramine 
and protriptyline) and that this reversal was not immediate, but 
required many hours before maximum antagonism was seen. Furthermore, 
after discontinuation of the antidepressant, a latent period of about 
five days was required before re-establishment of effective anti­
hypertensive activity (Figure 42). Similar interactions have been 
reported with other guanethidine-related drugs, such as bethanidine and 
debrisoquine (Figure 43) (Mitchell et al 19^7> 1970) and. more recently 
with clonidine (Briant, Reid and Dollery 1973)*
The pharmacological effect of' these antihypertensives has been 
shown to depend on their transport to sites of action within adrenergic 
neurones by the transport system that is responsible for the uptake of 
noradrenaline, the noradrenaline npumpM. This system also transports 
several indirectly acting adrenergic agents such as ephedrine and the
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amphetamines to their respective sites of action, (Gulati et al 1966).
It is probable that the tricyclic antidepressants block the action of 
this pump, and the uptake of the antihypertensives (Figure 44)* Ehe 
hypotensive action of methyldopa, however, is not usually affected 
because it enters the neurone by a completely different mechanism# 
Nevertheless, there has been one unexplained and isolated case in which 
antagonism apparently occurred. "White (19&5) reported that 
amitriptyline produced agitation, a fine tremor in the hands and 
tachycardia and reduced the antihypertensive effect of methyldopa in a 
single patient# Animal studies have subsequently provided further 
evidence for this interaction (Kale and Satoskar 1970)*
4.4.2. Synergism at the recentor
Bather than participating in competition at receptor sites, two 
drugs with similar intrinsic activities may act on common receptors or 
sites of action to produce an enhanced response# For example, if 
anticholinergic agents are combined, or if anticholinergic agents are 
used with other drugs which have an anticholinergic component in their 
action, such as various antiparkinsonian drugs or tricyclic 
antidepressants, excess anticholinergic activity may result# This 
effect was observed by the present author when the combination of a 
small dose of an anticholinergic drug and a tricyclic antidepressant 
(imipramine) produced troublesome urinary hesitancy and retention in a 
60 year old female patient. Withdrawal of the anticholinergic drug 
restored normal bladder function#
But this interaction has been associated with a much more dramatic 
and even fatal outcome. Wames et al (19&7) reported eight cases of 
chronic constipation with faecal impaction due to treatment with a 
phenothiazine, a tricyclic anti depressant, an antiparkinsonian drug or 
a combination of these drugs. Excessive anticholinergic activity had
Tricyclic antidepressants block the noradrenalineupump”and 
entry ot some drugs, eg. guanethidine.
FIGURE 44 Schematic representation of the mode of action of
tricyclic antidepressants at adrenergic neurones and 
their interference with the actions of other agents.
A highly simplified nerve ending is shown discharging 
noradrenaline whose re-uptake, and that of some 
hypotensives (e.g. guanethidine and bethanidine) is 
blocked by tricyclic antidepressants.
resulted in adynamic ileus# Five patients were treated successfully 
by disimpaction, nasogastric suction, intravenous fluid therapy and 
enemas but recognition of the condition was too late in three cases 
and a fatal outcome could not be prevented.
Dramatic results have also been reported when aminoglycoside 
antibiotics (e.g. gentamicin, kanamycin, neomycin and streptomycin) have 
been administered in the presence of surgical neuromuscular blocking 
agents. Prolonged muscular paralysis and apnoea have followed this 
combination as a result of synergistic interaction# Pittinger, Eryasa 
and Adamson (1970) reviewed more than 80 such incidents which had been 
recorded in the literature over the period 1955-1970# Many studies 
have shown that the aminoglycosides themselves produce neuromuscular 
blockade which may enhance the blockade of skeletal muscle relaxants.
4.4-3* Alteration of the receptor
Interactions based on alteration of the receptor usually involve 
some kind of sensitisation mechanism typified by digitalis toxicity 
occurring as a result of hypokalaemia and hypomagnesemia induced by 
concomitant diuretic therapy. Digitalis glycosides are believed to 
exert part of their cardiac effect by inhibition of ATPase which reduces 
the intracellular concentration of potassium. If this concentration 
is reduced further by diuretic-induced hypokalaemia, the ATPase system 
of myocardial cells is subjected to greater digitalis inhibition and 
the possibility of digitalis intoxication is markedly increased (Goodman 
and Gilman 1970; American Pharmaceutical Association 1973b)* 
liypomagnesemia predisposes to digitalis toxicity because it also 
augments the inhibition of ATPase induced by digitalis (Seller et al 1970)*
Alteration of the receptor has also been proposed as the mechanism 
underlying the potentiation of the anticoagulant effect of warfarin by
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thyroxine. Schrogie and Solomon (1967) and Solomon and Schrogie 
(1967b) suggested that a change in anticoagulant receptor site affinity 
induced by thyroxine might be responsible.
4.4*4* Alteration of other components at the site of action
Alteration of other components involved at the site of action is 
exemplified by the inhibition of monoamine oxide by monoamine oxidase 
(MAO) inhibitors. The increase in noradrenaline levels in various 
tissues which results from MAO inhibition is responsible for the 
hypertensive crises observed with combinations of MAO inhibitors and 
drugs which act by releasing noradrenaline, e.g. the indirectly acting 
adrenergic agents ephedrine (Low-Beer and Tidmarsh 1963; ELis et al 
1967) phenylephrine (Elis et al 1967) and phenylpropanolamine (Tonks 
and LLoyd 1965; Cuthbert et al 1969; Humberstone 1969; Mason and 
Buckle 1969). The excess amounts of noradrenaline which accumulate 
during MAO inhibition are released by these adrenergic agents causing 
massive stimulation of receptors and an exaggerated pressor response. 
This has led to fatal intracranial haemorrhage.
Similar interactions may occur with drugs which possess MAO - 
inhibition as a side effect, e.g. isoniazid and furazolidone. In the 
latter case this is due to a metabolite of furazolidone - a hydrazine 
derivative - which has an appreciable amount of MAO inhibitory activity, 
comparable to that of pargyline (Stem et al 1967). ]j\irazolidone is 
normally used as an antibacterial agent only for periods of up to five 
days. This period is not long enough for sufficient metabolite to 
accumulate to exert significant MAO inhibitory activity (Pettinger, 
Soyangco and Oates 1968). If used for longer periods, however, 
furazolidone may behave like an MAO inhibitor and good experimental 
evidence from human studies has been presented to support this (stem 
et al 1967)*
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4.4*5* Modifications of the overall biological response
Certain combinations of drugs may act on different sites of the 
same system or different systems to modify the overall biological 
response* This type of pharmacodynamic interaction is responsible for 
the enhanced depression of the central nervous system which occurs 
relatively commonly with combinations of narcotic analgesics, 
tranquillisers, neuroleptic agents, sedatives and hypnotics (Boston 
Collaborative Drug Surveillance Program 1972)* A similar mechanism 
underlies the synergism between alcohol and various central nervous 
system depressants. A rather more complex mechanism is thought to 
be responsible for potentiation of the hypoglycaemic action of insulin 
and oral hypoglycaemics of the sulphonylurea type by beta adrenergic 
blocking agents (Abramson, Arky and Woeber 1^66; Kotler, Berman and 
Rubenstein 1966; Annotations 1967)* Part of the homeostatic response 
to hypoglycaemia is glycogenolysis and mobilisation of glucose due to 
sympathetic stimulation mediated by beta receptors in skeletal muscle 
(Abramson and Arky 1968)* Beta adrenergic blocking agents, therefore, 
may interrupt this component of the glucose regulatory system and leave 
the hypoglycaemic action of insulin and the sulphonylureas unopposed* 
This may have particular clinical significance when hepatic glycogen 
stores are depleted or unavailable, for example, in badly controlled 
diabetes or following starvation*
4*5* CONCLUSIONS
Based on mechanism of action it is impossible to classify many of 
the interactions reported in the literature. Good experimental 
evidence is often lacking. Some may be explained only in terms of a 
number of different mechanisms which may embrace all three phases of
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drug action. But perhaps more important than classification is the 
detection and systematic documentation of interactions which are of 
clinical significance. Knowledge of these interactions should then 
foster a critical approach to the therapeutic efficacy of drug treatment 
in general. This would not only avoid adverse drug interactions in 
terms of overdosage and toxic responses hut also loss of drug response 
which may assume greater importance in the individual patient than the 
well-known adverse drug interactions. These were the considerations 
that dictated the development of a drug interaction warning system#
C H A P T E R  5
INITIAL DEVELOPMENT OF 
THE DRUG INTERACTION WARNING SYSTEM
5. INITIAL DEVELOPMENT OF THE
DRUG INTERACTION WARNING SYSTEM
5.1. INTRODUCTION - CLINICAL PROBLEMS
A therapeutic problem encountered on a routine medical ward round 
provided the initial stimulus to develop some form of drug interaction 
warning system.
An elderly lady with a deep venous thrombosis had been admitted 
for anticoagulant treatment and had been established on warfarin. It 
was subsequently noted that some instability in her anticoagulant control 
had developed, the result of which was an enhanced anticoagulant effect 
which carried the inevitable risk of haemorrhage. A survey of her 
drug treatment revealed that with the onset of a painful, superficial 
thrombophlebitis, phenylbutazone had been added to her therapy and the 
instability dated from the introduction of this second drug. This 
suggested that an interaction between phenylbutazone and warfarin had 
led to the difficulties in anticoagulant control and this was endorsed 
by the experimental and clinical evidence already reviewed in Chapter 
4 of this thesis. It was obvious that combined phenylbutazone and 
warfarin therapy posed serious haemorrhagic threats to all patients in 
whom it was used, and it had been recommended that the combination 
should be avoided (American Pharmaceutical Association 1973a). This 
experience served to highlight the necessity of creating a system which 
would alert doctors to the dangers of prescribing certain other drugs 
with warfarin. Simple bed-side methods were explored, for example, 
the word INTERACTION could be stamped in bold, red capital letters on 
a patient's bed-head progress chart, to act as a daily reminder, but 
this was rejected largely on the. grounds that it was uninformative and 
could alarm both the patients and their relatives. As it was essential
to incorporate useful information into any warning system, a list of 
drugs which were known to interfere with established anticoagulant 
therapy (Table 11) was compiled, which could be placed at the bed-side 
of any patient on anticoagulant therapy or carried on the ward trolley 
during ward rounds. It was immediately apparent, however, that 
anticoagulants represented only one part of the interaction problem 
and it would, therefore, be necessary to widen the concept to embrace 
other groups of drugs known to be implicated in drug interactions, for 
example antihypertensives, anticonvulsants, tricyclic antidepressants, 
oral hypoglycaemics and monoamine oxidase inhibitors. This resulted 
in a dossier of papers which could only be presented in booklet form 
and this was thought to be somewhat unwieldly and impracticable. It 
did not represent any real advance over literature on the subject already 
published. It was also important to recognise that the problems 
presented by drug interactions were not confined to hospital practice 
and that any warning system would be equally relevant to general 
practitioners and pharmacists. It thus became obvious that it was 
essential to condense the necessary information on to some easily 
portable system which could be rapidly referred to and read at a glance.
Two important questions presented themselves:
1. How much information should be incorporated on to
a system which was primarily intended to serve as a 
guide to possible drug interactions?
2. How could the information already assembled be 
presented in as concise a form as possible?
In answer to question 1, it seemed essential to draw attention to 
well-documented interactions and to stress when a combination of drugs 
was potentially dangerous. No details of pharmacological mechanisms 
would be incorporated but the effects of an interaction on drug activity 
would be shown, as this would be highly relevant to the clinical situation.
BARBITURATES 
CHOLESTYRAMINE 
DICHLORALPHENAZONE 
ANTICOAGULANTS (WARFARIN) GLUTETHIMIDE
are INHIBITED by: GRISEOMJLYIN
(i.e. activity is reduced} "MANDRAX"
MEPROBAMATE
ORAL CONTRACEPTIVES
PRIMIDONE
ANTICOAGULANTS (WARFARIN) 
are POTENTIATED by:
(i.e. activity is increased)
ALCOHOL
ANABOLIC STEROIDS 
ASPIRIN
BROAD SPECTRUM ANTIBIOTICS
CHLORAL HYDRATE
CLOFIBRATE
ETHACRYNIC ACID
GUANETHIDINE
INDOMETHACIN
MEFENAMIC ACID
NALIDIXIC ACID
OXYPHENBUTAZONE
PHENYLBUTAZONE
PHENYTOIN
SULPHONAMtDES
THYROXINE
TABLE 11 List of drugs reported to interfere with established 
anticoagulant therapy.
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In drawing up the list of drugs which could interfere with 
anticoagulants, a simple classification had been used to divide the 
drugs into those which could inhibit anticoagulants, i.e. reduce their 
activity, rendering them less effective, and those which could potentiate 
anticoagulants, i.e. increase their activity, possibly to the point of 
toxicity. This simple classification seemed appropriate for the 
presentation of all drug interaction data in a concise form, and 
provided a solution to the problem presented by the second question. 
Certain interactions, however, had been associated with relatively 
serious, sometimes fatal consequences, and such drug combinations would 
require a separate ’’dangerous combination” category.
5.2. EVALUATION AND ORGANISATION OF M U G  INTERACTION INFORMATION
Comprehensive reviews of drug interactions (Martin 1971? Hansten 
1973; American Pharmaceutical Association 1973? Stockley 1974) 
suggested a group of nine drugs.or drug categories whose documentation 
had stressed the importance or frequency of interactions when these 
agents were used in combination with other drugs (Table 12). The 
literature was therefore scrutinised for interactions with each of 
these nine drugs or drug categories, each interaction being classified 
in the manner referred to above.
Nine sets of data resulted which had to be accommodated onto some 
form of warning device. Each set of data consisted of a ’’primary” 
drug interacting with a list of ’’secondary” drugs, thus:
ALLOHJRINOL
ANTICOAGULANTS
ANTICONVULSANTS
ANTIHYPERTENSIVES
ASPIRIN
BETA ADRENERGIC BLOCKERS 
MONOAMINE OXIDASE INHIBITORS 
ORAL HYPOGLYCAEMICS 
TRICYCLIC ANTIDEPRESSANTS
TABLE 12 Drugs frequently implicated in drug interactions.
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is potentiated by
drug
is inhibited by
’’Secondary”
drug(s)
It was also necessary to include ’’Secondary1'drugs which were 
potentiated or inhibited by ’’Primary” drugs, thus?
potentiates
inhibits
’’Secondary"
drug(s)
The warning system, therefore, had to be capable of showing 
four possible interactions between pairs of drugs, thus;
"Primary"
drug
is potentiated by 
—  potentiates —
is inhibited by 
  inhibits --
"Secondary"
drug(s)
and it had to highlight any interactions which were known to be harmful 
in man. Table 13 shows an example of each of these categories of 
interactions, accompanied by a representative list of references 
emphasising the volume of literature available on this subject*
The "Secondary" drugs comprised a list of 57 generic drugs or 
pharmacological categories in common use, shown in Table 14* One 
hundred and twenty four interactions between primary and secondary 
drugs were identified.
Primary drug 
or
drug category
Interaction Secondarydrug(s) Reference
Anti c oagul ant s 
notably Warfarin
are
potentiated by Phenylbutazone A
Tricyclic
Antidepressants potentiate Anticholinergics B
Anti coagulant s 
notably Warfarin
are
inhibited by Barbiturates C
Tricyclic
Antidepressants inhibit Guanethidine D
Monoamine oxidase 
inhibitors
DANGEROUS
COMBINATION
Sjympathomime tic 
amines (indirect 
acting) e.g. 
ephedrine, 
phenylpropanolamine
E
TABLE 13 Examples of categories of drug interactions included on
the drug interaction warning system, with appropriate 
references.
A. Eisen, 1964; 19^45 Aggeler et al, 1967; Hoffbrand and 
KLninmonth, 1967; Solomon and Schrogie, 1967a and b; O'Reilly 
and Aggeler, 1968; Udall, 1969; O’Reilly and Aggeler, 1970; 
O'Reilly and Levy, 1970; Koch-Weser and Sellers, 1971;
Sellers and Koch-Weser, 1971; Lewis et al, 1974»
B. Kessell et al, 1967; Rogers, 1967; Wames, Lehman and Ban, 
1967; Milner, 1969*
C. Cucinell, Conney and Sansur, 1965; Goss and Dickhaus, 1965; 
Lewis, 1966; Robinson and MacDonald, 1966; MacDonald and 
Robinson, 1968; Aggeler and O’Reilly, 1969; MacDonald et al, 
1969; Levy, 1970; O'Reilly and Aggeler, 1970; Breckenridge 
and Orme, 1971; Koch-Weser and Sellers, 1971*
D. Leishman, Matthews and Sinith, 1963; Mitchell, Arias and Oates, 
1967; Mitchell et al, 1970; Iversen, 1971*
E. Scherbel, 1961; Zeck, 1961; Dalby, 1962; Mason, 1962;
Stark, 1962; Brownlee and Williams, 1963; Low-Beer and 
Tidmarsh,1963; MacDonald, 1963; Nymark and Nielsen, 1963; 
Tonks and Livingstone, 1963; Goldberg, 1964; Horowitz et al, 
1964; Lewis, 1965; Lloyd and Walker, 1965; Sjoqvist, 1965; 
Tonks and LLoyd, 1965; Elis et al, 1967; Cuthbert, Greenberg 
and Morley, 1$6$; Eumberstone, 1969; Krisko, Lewis and 
Johnson, 1969; Mason and Buckle, 1969; Lader, Sakai is and 
Tansella, 1970.
TABLE 13 continued References.
ALCOHOL FRUSEMIDE
ANABOLIC STEROIDS GLUTETHIMIDE
ANAESTHETICS (General) GRISEOFULVIN
ANTICHOLINERGICS GUANETHIDINE
ANTICOAGULANTS HYPOGLYCAEMICS (Oral)
ANTICONVULSANTS INDOMETHACIN
ANTIDEPRESSANTS (Tricyclic) INSULIN
ANTIHISTAMINES L-DOPA
ASPIRIN MEFENAMIC ACID
AZATHIOPRINE MEPROBAMATE
BARBITURATES 6-MERCAPTOPURINE
BETA-ADRENERGIC BLOCKERS METHAQUALONE
BENZODIAZEPINES METHOTREXATE
BETHANIDINE METHYLDOPA
BROAD SPECTRUM ANTIBIOTICS MORPHINE
CARBAMAZEPINE NALIDIXIC ACID
CHLORAL HYDRATE NARCOTICS
CHOLESTYRAMINE OXYPHENBUTAZONE
CLOFIBRATE PARACETAMOL
CONTRACEPTIVES (Oral) PHENOTHIAZINES
CORTICOSTEROIDS PHENYLBUTAZONE
DIAZEPAM PHENYTOIN
DICHLORALPHENAZONE PRIMIDONE
DIGOXIN PROBENECID
DIURETICS SULPHONAMIDES
ETHACRYNIC ACID SULPHONYLUREAS
FENFLURAMINE SYMPATHQMIMETICS
FLUFENAMIC ACID THYROXINE
TOLBUTAMIDE
TABLE 14 List of drugs in common use included on the 
drug interaction warning system#
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5.3. PRESENTATION OF DRUG INTERACTION INFORMATION 
5.3.1. Reference devices
Having assembled and classified all this information it was then 
necessary to present it in as compact a form as possible, with portability, 
clarity, and simplicity in use as the prime objectives. Two types of 
device appeared to satisfy these requirements - the slide rule and the 
circular reference disc. As the latter seemed to offer more in the way 
of design possibilities, this system was adopted in principle, and several 
examples of circular reference discs and calculators were studied to see 
how this format could be modified to accommodate drug interaction 
information. Two examples of such devices are illustrated in Figures 45 
and 4^. Roth consisted of a reversible unit of two concentric 
superimposed discs which pivoted about a common centre. The BIS device 
(Figure 45) gave information on the quality and composition of sand 
appropriate for moulds and cores in the iron, alloy and steel industry, 
and the caterers'calculator (Figure 46) was designed to assist in stock 
control and pricing calculations. Other devices examined included 
gestation calculators, exposure calculators used in photography and 
circular reference systems used to assess central heating requirements.
5.3.2* Cardboard prototypes of the drug interaction warning system
The nature of the drug interaction information dictated that the 
nine primary drugs should be brought into opposition with the fifty seven 
secondary drugs to indicate whether or not an interaction would occur.
This was achieved by arranging the secondary drugs along radii on the 
periphery of a large disc and the primary drugs on a series of arcs on 
a smaller disc. Each arc converged on a narrow window cut into the
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smaller disc and the two discs rotated freely about a common centre. 
Interactions between primary and secondary drugs were indicated by a 
series of colours which appeared in the window. Figure 47 shows the 
cardboard prototype disc which demonstrates all these features. The 
nine primary drugs were referred to as ’’inner drugs” and the secondary 
drugs as ’’outer drugs”. Interactions between any two drug combinations 
were indicated thus:
- OUTER DRUG INCREASES
- OUTER DRUG DECREASES
- INNER DRUG INCREASES
- INNER DRUG DECREASES
INNER DRUG ACTIVITY
OUTER DRUG ACTIVITY
This was in accordance with the inhibition-potentiation classification 
of drug interactions already decided on. A key to the colours appeared 
on the smaller disc.
A second prototype, shown in Figure 48, included the category of 
interaction which was known to result in harmful effects, i.e. a 
DANGEROUS COMBINATION, indicated by a distinct symbol - a white diagonal 
stripe on a black background, and a slightly different series of colours 
was used. These cardboard prototypes measured 21 cm. in diameter and 
established the design of the drug interaction warning system upon which 
all subsequent developments were based.
5.4. THE DRUG DISC
In the prevailing climate of anxiety engendered by multiple drug 
therapy and adverse drug interactions, it seemed pertinent to submit this 
warning system for publication, and the Methods and Devices Section of 
the Lancet seemed most appropriate. The second prototype was, therefore,
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adapted for publication in association with Mr. P.S. Waldie, Head of 
the Department of Audio-Visual Services at Stobhill General Hospital, 
Glasgow. Because of the limitations imposed on printing in such a 
journal, the warning system had then to be conceived in black and white, 
and a series of black and white symbols replaced the prototype colours, 
thus:
- OUTER DRUG INCREASES
- OUTER DRUG DECREASES
- INNER DRUG INCREASES
INNER DRUG DECREASES
INNER DRUG ACTIVITY
OUTER DRUG ACTIVITY
- DANGEROUS COMBINATION
This version of the warning system (Figure 49)» subsequently 
referred to as the Drug Disc, measured 15 cm. in diameter and was 
published in the Lancet on May 12th, 1973 (Whiting, Goldberg and Waldie 
1973).
5.4.1® Response to the Drug Disc -publication
This article immediately provoked a remarkable degree of interest 
throughout the world, as did a subsequent article in the .American Journal, 
Drug Therapy (Whiting, Goldberg and Waldie 1974). A number of independent 
reviews appeared in various languages and the system was demonstrated on 
the B.B.C. Television programme "Tomorrow's World".
One thousand one hundred and fifty letters enquiring about the Drug 
Disc were received from doctors, pharmacists, students, pharmaceutical 
companies, drug regulatory bodies and various other official organisations.
FIGURE 49 The Drug Disc as published in the 
Lancet, showing the complete system 
and detail of the large disc.
An analysis of this response appears in Tables 15-19* It wa-s obvious 
that the Drug Disc had been well received and represented a growing need 
for this type of approach to the problem of drug interactions.
The response from pharmaceutical and commercial concerns had been 
anticipated, and a copyright protection of the disc had been applied 
for and obtained on 25th April, 1973* Direct association of the Disc 
with commercial interests, exemplified by the pharmaceutical industry, 
was thought to be inadvisable and requests for access to the copyright 
from such sources were therefore denied*
5*4*2. The Working Party
The extent of the response on the part of other groups such as 
doctors and pharmacists prompted careful consideration of how the Disc 
could be made generally available. It obviously required official 
support and approval and it seemed most appropriate to make an approach 
to the Scottish Home and Health Department. This approach was welcomed 
and subsequently led to the formation of a Working Party whose remit was 
advise on further development of the drug interaction warning system, 
submit it to trial in the United Kingdom, and then to effect its free 
distribution to all doctors working in the National Health Service.
Members of the Working Party included:
1* Professor A. Goldberg, Department of Materia Medica,
University of Glasgow.
2. Professor J. Crooks, Department of Pharmacology and 
Therapeutics, University of Dundee.
3* Dr. B* Whiting, Department of Materia Medica,
University of Glasgow.
4* Mr. P*S. Waldie, Department of Audio-Visual Services,
Stobhill General Hospital, Glasgow*
D O C T O R S
Geographical
area Category
Number of 
letters
United Kingdom Hospitals and Universities 60
General practitioners 70
U.S.A. Hospitals and Universities 450
Canada Hospitals mainly 20
Europe Hospitals mainly 80
Other parts of the world, mainly from hospitals: 
Argentina, Australia, Czechoslovakia, Hong Kong, 
Hungary, India, Israel, Japan, Kenya, Mexico, 
New Zealand, Pacific Islands, Rhodesia, South 
Africa, Tunisia, Turkey.
60
Total 740
TABLE 15 Worldwide response of doctors to articles and 
reviews about the Drug Disc0
P H A R M A ' C I S T S
Geographical area Number of letters
United Kingdom 45
Other countries - mainly 
U.S.A. 70
Total 115
TABLE 16 Worldwide response of pharmacists to articles 
and reviews ahout the Drug Disc*
STUDENTS and NURSES
Geographical area Number of letters
Students (medical, 
pharmacy and
pharmaceutical technology), 
mainly United Kingdom, 
Erance and Germany*
40
Nurses, mainly United 
Kingdom. 30
Total 70
TABLE 17 Worldwide response of students and nurses to 
articles and reviews ahout the Drug Disc*
OFFICIAL ORGANISATION S
Geographical area and organisation Number of letters
United Kingdom, including:
The Department of Health and Social 
Security.
The Ministry of Health and Social 
Services (Northern Ireland).
The British Industrial Biological 
Research Association.
The Ministry of Defence.
The Joint Pricing Committee for 
England.
The National Pharmaceutical Union. 
The Association of the British 
• Pharmaceutical Industry.
The Psychiatric Rehabilitation 
Association.
10
Other countries, including:
Switzerland
The World Health Organisation. 
Czechoslovakia
State Institute for the Control of Drugs. 
U.S.A.
United States Pharmacopoeia.
Poison and Drug Information Centres.
35
Total 45
TABLE 18 Worldwide response of official organisations to 
articles and reviews about the Drug Disc®
PHARMACEUTICAL AND COMMERCIAL INTEREST
Enquiries and requests for acquisition of.copyright, 
subsequent manufacture and distribution of the Drug Disc 
in its original or modified form came from companies in the
following countries:
ANGOLA
ARGENTINA
AUSTRALIA
BELGIUM
CANADA
COSTA RICA
DENMARK
FRANCE
GERMANY
GREECE
HOLLAND
ITALY
Total number of
JAPAN
MEXICO
NORWAY
RHODESIA
SOUTH AFRICA
SPAIN
SWEDEN
SWITZERLAND
UNITED KINGDOM
UNITED STATES OF AMERICA
VENEZUELA
letters 180
TABLE 19 Worldwide response of pharmaceutical companies and 
other commercial companies to articles and reviews 
about the Drug Disc*
5* Members of the Scottish Home and Health Department 
including Dr. G.D. Forwell, Dr. I.S. McDonald,
Dr. G.A. Scott and Dr. A.T.B. Moir.
6. Representatives from Her Majesty's Stationery Office.
5.5. LEGAL AND ETHICAL CONSIDERATIONS
Advice was sought on legal and ethical aspects of copyright and 
patenting in the medical field. This was the subject of a full 
enquiry by the Council of the British Medical Association (British 
Medical Association 1950, 1970) which approved of patenting in the 
medical field by members of the profession, provided that the patent,
(in this case copyright of the Drug Interaction Warning System) was 
offered and assigned to the National Research Development Corporation 
(NRDC). This corporation was set up in 1949 under the Development 
of Inventions Act to give financial support to a variety of University 
and Polytechnic inventions which showed promise, although speculative, 
of having commercial value. Any assignation to the NRDC would ensure 
that the invention to which the patent related would be made available, 
developed and exploited in the best interests of the public. The 
present author, therefore, submitted the Drug Disc to the NRDC. After 
due consideration they came to the conclusion that they could offer no 
more assistance in Britain than was being given by the Scottish Home 
and Health Department and that their involvement would be superfluous.
The important point was made that the "best interests of the public" 
would be served by the free distribution of the Disc to doctors 
throughout the United Kingdom. No further action on the part of the 
NRDC was therefore necessary*
As a large part of the response to the articles about the Drug 
Disc stemmed from abroad, it was important to bear in mind the possibility
of worldwide distribution. This would inevitably involve commercial 
considerations. Further advice on the ethical and professional 
aspects of this kind of involvement was therefore sought fromm Messrs. 
Eempsons of London, Solicitors to the British Medical Association and 
General Medical Council. They advised that nothing in the British 
Medical Association's ethical rulings would hinder plans for a worldwide 
distribution and strongly recommended an association with a reputable 
international publishing company specialising in medical literature.
5.6. SECOND VERSION OF THE DRUG DISC
5*6.1. Modifications
Having accepted the concept of the drug interaction warning system 
in principle, the Working Party examined the prototype (Lancet version) 
and agreed on three important modifications:
1. An increase in the capacity of the system by utilising both
sides of the large disc, forming a reversible unit.
2. The introduction of colour, as printing of subsequent versions 
of the Disc would not be restricted to black and white.
3* The use of a durable material such as plastic rather than
the grade four glossy bromide photographic paper used to 
construct several prototypes (Lancet version, Figure 49)*
Daily handling of these prototypes had soon demonstrated 
the need for stronger materials.
Two small discs, affixed to opposite sides of the large disc and 
rotating about a common centre effectively increased the capacity of 
the system and formed the basis for the second version of the Drug Disc* 
Sixteen primary drugs could now be accommodated on the small discs, 
eight on each side. The primary drugs were therefore increased to
include the original nine shown in Table 12 and seven others known to 
be implicated in drug interactions, including alcohol, shown in Table 20.
As in the prototype, each drug was placed on an arc converging on an 
arrow-like window. Seven additional drugs were also added to those 
appearing on the large disc, which then contained an-identical list of 
64 drugs or drug categories printed in alphabetical order on each side.
5.6*2. Introduction of coloured symbols
The use of colour provided a means of introducing a more logical 
key system incorporating internationally recognised symbols for 
potentiation a PLUS sign, and inhibition - a MINUS sign. Dangerous
combinations would still be indicated by a diagonal cross. The new
key system was realised by printing the drugs on the smaller discs in 
red and the drugs on both sides of the larger disc in black, subsequently 
referred to as "red" and "black" drugs respectively. The symbols used 
were chosen from those shown in Figure 50 • Apart from the diagonal 
cross motif, the background colour of a symbol denoted the drug (red or 
black) whose action was modified, while the plus or minus symbol expressed 
the direction of the altered pharmacological activity in terms of 
potentiation or inhibition. Table 21 shows examples which will illustrate 
this system.
It was hoped that the use of these symbols would appeal to the user’s 
sense of logic, thus avoiding the necessity for detailed instructions* 
Indeed, no problems in interpretation were encountered when the symbols 
were shown to twenty of the present author’s medical colleagues.
5.7. UNITED KINGDOM TRIAL VERSION OF THE DRUG DISC
As the second version of the Disc would be submitted for trial in
ALCOHOL
AMINOGLYCOSIDE ANTIBIOTICS
ANTACIDS
BARBITURATES
CORTICOSTEROIDS
ORAL CONTRACEPTIVES
PHENOTHIAZINES
TABLE 20 Additional drugs to be 
included on the small 
discs.
++ +
FIGURE 50 Series of coloured symbols 
considered for use on the 
Drug Disc.
COUMARIN ANTICOAGULANTS (Red Drug) and CLOFIBRATE (Black Drug)
RED DRUG is potentiated, i.e. 
coumarin anticoagulants are potentiated 
by clofibrateo
AMINOGLYCOSIDE ANTIBIOTICS (Red Drug) and MUSCLE RELAXANTS
(Black Drug)
BLACK DRUG is potentiated, i«e. 
muscle relaxants are potentiated by 
aminoglycoside antibiotics.
COUMARIN ANTICOAGULANTS (Red Drug) and DICHLORALPHENAZONE
(Black Drug)
RED DRUG is inhibited, i.e. coumarin 
anticoagulants are inhibited by 
dichloralphenazone•
TRICYCLIC ANTIDEPRESSANTS (Red Drug) and CLONIDINE (Black Drug)
BLACK DRUG is inhibited, i.e. Clonidine is 
inhibited by tricyclic antidepressants.
MONOAMINE OXIDASE INHIBITORS (Red Drug) and PETHIDINE (Black Drug)
DANGEROUS COMBINATION or POTENTIALLY SERIOUS 
INTERACTION.
+
+
TABLE 21 Examples of the use of coloured symbols on the second 
version of the Drug Disc.
the United Kingdom, arrangements were made for its production in plastic 
by Her Majesty's Stationery Office (H.M.S.O), A series of drafts 
prepared by the present author and Mr. P.S. Waldie were reviewed by 
the Working Party and the form shown in Figure 51 was finally accepted. 
Although copyright had been obtained in April 1973 By registration at 
Stationers Hall (Entry No.7822), Fitzpatricks, Chartered Patent Agents, 
advised further protection of the device by inclusion and registration 
of the trademark MEDISC. This can be seen in Figure 51*
The final draft of the second version was discussed with H.M.S.O., 
who agreed to produce about 500 Discs for the United Kingdom Trial.
A plastic pocket for each Disc would also be provided, which would 
display the trademark and a cautionary note advising the user that the 
Disc was intended only as a guide, and that the appropriate 
pharmacological literature should be consulted for more detailed 
information.
Figures 52 and 53 show details of the trial version which was 
received from H.M.S.O., in December 1973* The only significant 
departure from the final draft (Figure 51) was a change in the 
"potentially serious interaction" motif - the black cross on a red 
background had been replaced by a red cross on a white background.
The words "potentially serious interaction" had also been printed in 
red. The device measured 14 cm. in diameter and was made of a semi­
rigid plastic material.
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FIGURE 51 Draft of the United Kingdom Trial version 
of the Drug Disc, showing both sides.
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version of the Drug Disc with detail 
of the large disc.
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FIGURE 53 Side 2 of the United Kingdom Trial
version of the Drug Disc with detail 
of the large disc.
C H A P T E R  6 
UNITED KINGDOM TRIAL OF THE DRUG INTERACTION WARNING SYSTEM
6* UNITED KINGDOM TRIAL OF THE DRUG INTERACTION WARNING SYSTEM
The aim of the trial was to assess the value of the drug interaction 
warning system in practice by exposing it to as many different clinical 
and scientifically relevant situations as possible* It was originally 
planned to conduct the trial in two phases, separated by one month, 
(Phases 1 and 2) but the lack of response on the part of some 
participants called for a third phase (Phase 3)o Details of these 
phases are shown in Figure 54*
6*1* PHASE 1
Four hundred and fifty doctors and pharmacists, distributed as 
shown in Table 22 were invited to take part in the trial*
Each participant received:
1* A Drug Disc* contained in a plastic pocket (Figures 52 and 53)* 
2* An explanatory letter from the Department of Materia Medica,
University of Glasgow, (Figure 55 )•
3* A questionnaire (HInitial Report”, Figure 56) which was to
be returned within one week to gain some impression of the
immediate reaction to the Drug Disc*
The Initial Report sought answers to seven questions, which covered 
the design of the Disc, including the key system (Questions 1-4)» the 
relevance of the information presented to clinical practice (Question 5)> 
the usefulness of the system (Question 6) and Question 7 allowed for any 
further comments, including those of colleagues, to encourage an even 
wider distribution*
SECOND QUESTIONNAIRE 
(“FOLLOW UP REPORT”)
AFTER 1 MONTH
PHASE 2
COMPOSITE QUESTIONNAIRE 
(“EVALUATION REPORT”)
IF NO RESPONSE
PHASE 3
Distribution of:
DRUG DISC
Explanatory letter 
FIRST QUESTIONNAIRE 
(“INITIAL REPORT”) 
to be returned 
within 1 week
PHASE 1
FIGURE 54 Details of the three phases of the United Kingdom Trial 
of the Drug Disc,
1* A group of EXPERTS, including Senior Lecturers and 
Professors of CLINICAL PHARMACOLOGY 
PHARMACOLOGY 
MEDICINE 
PHARMACY
PHARMACEUTICAL CHEMISTRY
2, HOSPITAL DOCTORS in all grades and specialities in
ABERDEEN
DUNDEE
EDINBURGH
GLASGOW
INVERNESS
MANCHESTER
3* GENERAL PRACTITIONERS throughout the United Kingdom
4. HOSPITAL and AREA PHARMACISTS in Scotland
5® A miscellaneous group, including MEDICAL OFFICERS in the 
ROYAL AIR FORCE stationed in the United Kingdom, Germany 
and Cyprus, and various official organisations.
TABLE 22 United Kingdom Trial : distribution list.
T h e  UNIVERSITY o f  GLASGOW
D e p a r tm e n t  o f  M a t e r ia  M e d ic a  
S t o b h i l l  G e n e r a l  H o s p ita l  
G la s g o w , G21 3UW
T e le p h o n e :  041-558 5042 
E x te n s io n :  561
December 1973 
Dear Colleague,
THE DRUG DISC
On May 12 this year, Dr Brian Whiting, Mr Peter Waldie and I  published a paper in the Lancet on the Drug 
Disc. This was intended to be a warning in the form of an aide-memoire to doctors and pharmacists against 
adverse drug interactions. The publication aroused considerable interest. As a result, a Working Party was 
formed at the Scottish Home and Health Department at St Andrew’s House, Edinburgh. This included 
members of the medical staff of the Scottish Home and Health Department and the Department of Health 
and Social Security in addition to Professor J Crooks of Dundee, Dr Whiting and myself. The aim of 
this group was to develop the disc for wide distribution to hospital doctors, general practitioners and 
pharmacists in this country.
We have improved the original disc and I  enclose the latest version for your comments as I  know this w ill 
be of interest to you. I t  would be helpful to have your in itia l reaction to the disc and your comments after 
you have used it  for one month. To facilitate this, I  am enclosing a questionnaire and in one month’s time 
I  w ill send you a second questionnaire. It  would also be helpful i f  you could show it  to any of your collea­
gues who might be interested and record their views under “any further comments”.
On the basis of the completed questionnaires we w ill modify the present disc and produce a final one for 
general distribution.
I  am most grateful for your anticipated collaboration.
Yours sincerely,
A GOLDBERG, MD, DSc, FRCP, FRSE
FIGURE 55 Explanatory letter sent out
at the beginning of the United 
Kingdom Trial,
THE DRUG DISC
Warning system for drug interactions
EVALUATION 
IN IT IA L  R EPO R T
We would like to gain some impression of your in itia l reaction to the Drug Disc. Would you please answer 
the following questions and return the top form within one week as an acknowledgement that you have 
received the disc. Retain the duplicate copy for your further reference.
Where you give a negative response to any of the first five questions, could you give your reasons and 
suggested changes under item 7.
1. Is the method of using the Disc readily
understandable?____________________________ '   Yes/N o*
2. Are the interaction symbols clear?_______   Yes/N o*
3. Is  the Key clear?_____________________________________________________________________  Yes/N o*
4. Is  the size convenient?_____________________________   Y es/N o*
5. Do you think the interactions shown are relevant
to clinical practice?_________________________________________________________________  Yes/N o*
6. What is your in itia l overall impression of its usefulness?
Very useful/useful/of limited use/of no use*.
7. Any further comments, including those of colleagues where appropriate
Please return to:
Department of Materia Medica 
Stobhill Hospital 
Glasgow G21 3UW.
♦Delete as applicable
Name______
D a te ______
Designation
Address
FIGURE 56
6,2, PHASE 2
One month later, a second questionnaire ("Follow TJp Report",
Figure 57) was sent to each participant to find out whether use of 
the Disc during the trial period had altered the initial impression 
of its value (Questions 1 and 2). Its effect on drug administration 
(Question 3) and its value in teaching (Question 5) were also assessed. 
Suggestions for its improvement were invited (Question 4) and again, 
a space was provided for any other relevant comments, including those 
of colleagues (Question 6),
6.3. PHASE 3
Phase 3 was necessary because some participants failed to return 
one or both reports relating to Phases 1 and 2. A second approach 
was considered worthwhile and 160 modified questionnaires ("Evaluation 
Report", Figure 58) based on the Initial and Follow Up Reports, were 
distributed accordingly.
6.4. RESULTS 
6,4.1* Response
The overall response to the three questionnaires is shown in 
Table 23, while the detailed response of the various groups involved 
is shown in Table 24* Two hundred and eighteen (48$) participants 
completed the trial satisfactorily before the institution of Phase 3.
A further 95 then responded to the second approach, increasing the total 
number completing the trial to 313 (70$)« These results are expressed 
graphically in Figure 59, and. Figure 60 illustrates the different responses 
of the major groups at each stage of the trial.
'• THE DRUG DISC 
V/arning system for drug interactions
EVALUATION
FOLLOW UP REPORT
We would now like your comments after you have used the Drug Disc for one month.
1. What was your initial overall assessment?
Very useful/useful/of limited use/of no use*.
2. Has using the disc for one month altered your 
in itia l assessment?___________________ _____ , Yes/No.
I f  yes, what is your final assessment?
3. Has it modified your drug administration at any 
time?
Very useful/useful/of limited use/of no use. 
________   Y  es/No.
4. Do you have any suggestions for its improvement?.
5. Do you think it may have value in teaching?_________
6. Any further comments, including those of colleagues 
where appropriate
, Yes/No.
Please return to 
Department of Materia Medica 
Stobhill General Hospital 
Glasgow G21 3UW
♦Delete as applicable
Name
Date
Designation
Address
FIGURE 57
THE DRUG DISC
Warning system for drug interactions, 
EVALUATION REPORT,
We would like to gain some impression of your reaction to the Drug Disc. 
Would you please answer the following questions and return the form to 
me within one week.
Where you give a negative response to any of the first five questions, 
could you give your reasons and suggested changes under item 9*
lo Is the method of using the Disc readily
understandable?  .............     ....«>..Yes/No •
2. Are the interaction symbols clear? .©..............«,.©, Yes/No.
3. Is the Key clear?  ..........    Yes/No.
4. Is the size convenient?  ......    Yes/No.
5. Do you think the interactions shown are relevant to
clinical practice? .......       ...... o, Yes/No.
6. Has it modified your drug administration at any time?
   .............        Yes/No,
7. Do you think it may have value in teaching? Yes/No.
8. What is your overall impression of its 
usefulness?
Very useful/useful/of limited use/of no use0
9o Any further comments, including those of colleagues 
where appropriate?
Please return to:
Department of Materia Medica, 
Stobhill General Hospital, 
Glasgow, G21 3UW
Name..., 
Date..., 
Address,
FIGURE 58
PHASE QUESTIONNAIRES
Distributed Returned
1 450 285 (63$)
2 450 218 (48 $)
3 160 95 {59%)
All phases ** 313 (70$)
TABLE 23 United Kingdom Trial : overall response
to questionnaires®
To
ta
l 
nu
mb
er
 
co
mp
le
te
d 
tr
ia
l
§c—
r-
$vo
•^4
VO
pH
S
VO
'vf
KN
f
VO
CM
KN
?
VO
00
rH
s
VO
KN
c—
VO
£
UN
KN
00
voCM
KN
ON
1^"
rH
UN [—
VO
UN00
ONCM
C—
KN
rH
KN
KN
HCO
aPH
c
•r
C
c•r4Cc
d
<
c£
!2
q
d a) 
-• PS  ^ H t3 3
3 +* 3 0 
M
QI)
I
voc— VOrH ’■cj-CM 00 unCM CM rH 00 CM 1 ON
f—>
*
UN
UN
ON
5?
HD 4>
H PJ
D O3 co t
KN
KN
rH
O
KN
O
KN
O
rH
lf\
UN
CM
rH
KN I CM
rH
O
VO
rH
Nu
mb
er
 
of 
Qu
es
ti
on
na
ir
es
 
re
tu
rn
ed
cm
%
r~- 00GO «0rH 00 OrH 00 CM CM 00rH CMrH vo OCM
?
00
rHCM
rl
WCO r—co ONCM
rH
1—1CM UN 1—1 t-CM CMVO CM CM 00rH rH vo rHKN
KN
VO
UN0OCM
Nu
mb
er
 
of
 
di
sc
s 
se
nt
00iH
KN
VOCM
O
un
O
UN
O
KN
rHCM 1—1
VO VO O
kn
ON
rH
CO
KN
O
UN
&
0
COas0ME4H
••
a0
0 a  co US O S  0 CO EH O W K ^ H CO
 ^ I  1 § S I -S § fl i  0 H  1
s
CO
1
<£M  CO 
Ph Eh CO CO O  Hw 0
'p aal
lj ^
pq0sf=H
0
<
hP
0
COB
gCO
B
•«
CO
eJ0
Eh
TA
BL
E)
 
24 
Un
it
ed
 
Ki
ng
do
m 
Tr
ia
l 
: 
de
ta
il
s 
of 
th
e 
re
sp
on
se
 
of 
th
e 
di
ff
er
en
t 
gr
ou
ps
 
pa
rt
ic
ip
at
in
g 
in 
th
e 
tr
ia
l
°/o
 
Pa
rt
ic
ip
an
ts
 
Re
tu
rn
in
g 
R
ep
or
ts
100-.
9 0-
8 0-
70-
60-
50-
40-
30-
20-
10-
r uui
00(
5 00 A£U
PHASE 1
PHASE 2
PHASE 3
OVERALL
RESPONSE
ooooo ooooo oooooc ooooo ooooo ooooc ooooo p>ooooc ooooo ooooc ooooo ooooc ooooo ooooc ooooo ooooc ooooo ooooc ooooo ooooc ooooo ooooc ooooo ooooc ooooo ooooc ooooo ooooo oooooc; oooooo ooooo oooooc ooooo ooooo ooooc ooooo ooooo
m
D<XX>t>ooooo< VVVVyil
285, 218, 95, 313,
4 5 0  4 5 0  4 6 0  4 5 0
FIGURE 59 United Kingdom Trial : Graphical representation of the
overall response.
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Hospital
Doctors
(263)
General
Practitioners
Experts Area and Hospital 
Pharmacists
(100) (30) (15)
60 United Kingdom 'Trial : details of the response of the
major groups participating in the trial.
The overall responses of hospital* doctors was represented by a 
62$ return, and as Figure 61 shows,, there was very little variation in 
this overall response throughout hospitals in Scotland. However, when 
the response of individual hospitals in the Glasgow Area was examined, 
it varied quite markedly from 45$ to 83$, as shown in Figure 620
6.4*2* Answers
An analysis of the answers given on the 598 reports returned in 
the three phases of the trial is shown in Tables 25 and 26.
As the Evaluation Report sent out in Phase 3 merely duplicated 
the questions asked in Phases 1 and 2, no separate assessment of Phase 
3 was necessary. Answers were included in the appropriate Initial or 
Follow Up Report data as appropriate.
Table 25 clearly demonstrates that the majority of participants 
considered that the Disc was easy to use, the symbols were clear, the 
key was clear, and the interactions were relevant to clinical practice. 
The response to Question 4 suggested that a slight reduction in size 
would be an advantage. The response to Question 6 reflected the 
enthusiasm with which the Disc had been received - 85$ rated it useful 
or very useful. The majority who thought it would be of limited use 
were paediatricians, obstetricians and anaesthetists, whose practice 
dictated the use of a relatively specialised range of drugs.
Table 26 shows that 85$ of the participants completing the trial 
(313 reports) found no reason to change their initial assessment.
This figure may be a little high as no opportunity for a revision of 
initial rating could be given in Phase 3* Thus if Evaluation Reports 
are excluded the figure falls to 79$ (171 of 218 Follow Up Reports).
The 21$ (47 of 218 Follow Up Reports) who had changed their initial 
assessment were distributed as shown in Figure 63, and Table 27
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INITIAL REPORT
Question 1« Is the method of using the Disc 
readily understandable? 95?S Yes
Question 2. Are the interaction symbols 
clear? 95$ Yes
Question 3. Is the key clear? 94$ Yes
Question 4* Is the size convenient? 76$ Yes
Question 5* Bo you think the interactions 
are relevant to clinical 
practice? 90$ Yes
Question 6, T,Vhat is your initial overall 
impression of its usefulness?
Very useful 40$ v.;Q^  
Useful 45$
Of limited use 13$
Reserved comment 2$
TABLE 25 United Kingdom Trial, Initial Report j 
analysis of answers*
FOLLOW UP REPORT
Question 2. Has using the Disc for one month < 
altered your initial assessment? 85 f> No
Question 3« Has it modified your drug
administration at any time? 43%  Yes 
51 fo No
(6f> irrelevant)
Question 5® Ho you think it may have value 
in teaching? 80f> Yes 
15 fo No
(5fo irrelevant)
TABLE 26 United Kingdom Trial, Follow Up Report : analysis of
answers. Participants who found Questions 3 and 5 
irrelevant were those who neither administered drugs 
nor had the opportunity of teaching.
VERY USEFUL
1 M T 7_y_i
USEFUL (-12) 3 1
r
OF LIMITED USE
(-9)
(+17)
OF NO USE
FIGURE 63 United Kingdom Trial : details of the
participants revising their opinion of the 
Drug Disc during the course of the trial. 
Total number = 47 (21$ of Follow Up Reports). 
Net changes are shown in parenthesis*
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illustrates the effects of this change, and of the opinions expressed
in Phase 3, on the final overall assessment of the value of the Disc.
These changes in rating could not take account of those participants 
who completed Phase 1 hut failed to complete subsequent phases* However, 
the available data indicated that very little change in assessment 
occurred over the trial period, Q2fo completing all phases rating the 
Disc useful or very useful (Table 28)*
Again, the group who thought that the Disc would be of limited
use or of no use were largely represented by doctors using drugs in 
specialised circumstances, such as obstetrics, paediatrics and 
anaesthetics.
Some modification of drug administration attributable to the Disc 
during the trial period was reported by 43f<> of participants, and 80^ 
considered that it would be of value in teaching (Table 26#)
6.4*3* Recommendations
It was obvious from the response that many of the participants had 
considered the Disc very carefully, and a number of valuable suggestions 
were made under "any further comments"# These can be summarised as 
follows s
(a) Size The Disc would benefit from a slight reduction in 
diameter, which would enable it to fit into most pockets, 
o o  Construction Mechanically linking the smaller discs so that 
they rotated together might simplify its use# Only one 
operation would then be required to look up interactions 
occurring with drugs on the periphery of the Disc®
(c) Key system Improvement in the meaning of the key system
might be gained by some elaboration of the words "potentiated" 
and "inhibited"# The logic of the key system appeared to be
A S S E S S M E N T
INITIAL FINAL
VERY USEFUL 40 %
85 %
3 9%
82%
USEFUL 45 % 43%
OF LIMITED USE 13 % 17%
OF NO USE 1%
RESERVED COMMENT 2% *•
TABLE 28 United Kingdom Trial : comparison of
the initial and final assessments of 
the value of the Drug Disc#
87
satisfactory, but "potentially serious interactions" could 
be indicated by a more distinct symbol or colour#
(a) Content The information given on the Disc was in general
thought to be relevant to clinical practice, but more guidance 
should be given as to whether an interaction was clinically 
significant or not# This suggested the introduction of 
another category to show interactions which were of "doubtful 
clinical significance", e.g. interactions based on animal 
data which cannot be extrapolated directly to man, interactions 
derived from in vitro data which may not be related to conditions 
in vivo, interactions demonstrated in single-dose experiments 
in healthy volunteers, the results of which may not be relevant 
for patients on chronic dosage schedules, and interactions 
based on relatively poor scientific evidence - small patient 
or volunteer samples and single "case reports"#
The validity of certain interactions was questioned and 
the inclusion of others suggested.
Doctors engaged in certain specialities, notably obstetrics, 
paediatrics and anaesthetics, considered that the Disc was too 
general in its application and suggested the development of 
similar Discs which would relate solely to their own clinical 
situation. As interactions with general anaesthetics was a 
major subject in itself, it was suggested that "general 
anaesthetics" was too broad a category to be included and should, 
therefore, be removed from the Disc.
(e) Proprietary names Many general practitioners made a plea for 
the inclusion of proprietary names, particularly where drug 
categories such as tricyclic antidepressants and anticholinergics
were indicated# A separate "G.P. version" of the Disc was 
also suggested#
o o  Companion text Many participants suggested that a small 
booklet containing explanatory notes and reference sources 
could accompany the Disc# It was also suggested that a more 
comprehensive survey of drug interactions with appropriate 
references could be linked to the Disc#
6.5# DISCUSSION
It was very gratifying to obtain an overall trial response of 70%, 
as this yielded a great deal of useful information and comment which 
could then be incorporated into a final version of the Disc# Bearing 
in mind that the different groups involved in the Trial were of unequal 
size, the experts, pharmacists and general practitioners proved the 
most responsive, complementing the interest displayed in the Disc 
subsequent to its first publication# The response of the miscellaneous 
group (85%) was high because most of this group had expressed a 
particular interest in the Disc and had offered to participate in the 
Trial. There was little variation in the response of hospital doctors 
throughout Scotland (overall 62%) and the variation of 45% to 83% in 
individual hospitals in the Glasgow area could be partly attributable 
to the different numbers involved.
A market research survey of this kind with results based on a 
voluntary return can often fail to elicit a satisfactory response, but 
in general, this was not the case in this Trial. Phase 3 increased 
the response from 48% to 70% and was therefore an important component.
A review of answers to specific questions, comments, suggestions 
and criticisms indicated that the Disc had been received with obvious 
enthusiasm and would be of considerable value in practice# Certain 
modifications, however, were necessary, and would be incorporated into 
the final design, with the agreement of the Working Party# The Trial
89
had demonstrated the acceptance of the warning system in principle and 
its basic format, Hie most important modification would involve a 
reclassification of the interactions to distinguish clearly between 
those of clinical and those of doubtful clinical significance. Every 
interaction would be scrutinised and re-evaluated in the light of this 
new ’’doubtful clinical significance” category, which would be awarded a 
distinctive colour. Reference to clinically significant interactions 
shown in the key would be expanded to convey the concept of alteration 
in the therapeutic and/or toxic effect of one or other of the interacting 
drugs.
Having accepted that the amount of space on the small discs limited 
the number of primary (’’red”) drugs to sixteen (eight on each side), 
consideration would be given to suggestions about changes in these drugs 
which would stress the importance of certain interactions not shown on 
the Trial version.
The introduction of proprietary names would seriously compromise 
space and no further consideration would be given to this suggestion.
As the Disc was designed to be a convenient and rapid source of 
infonnation, any booklet giving details of drug interaction mechanisms 
and associated references would be somewhat superfluous and would defeat 
the basic objective of the system. But a small explanatory booklet 
outlining the rationale and operation of the Disc, with selected reference 
sources would undoubtedly enhance its use, The booklet could also stress 
that the Disc was not intended to be a complete compilation of drug 
interactions or a definitive authority for clinical use. An interaction 
revealed by a symbol or the presentation of information which might 
question the therapeutic value of a proposed regimen should induce 
confirmation of such facts before proceeding further with the medication. 
In this context, it would be appropriate to associate it with a national 
publication such as the British Rational Formulary.
90
The Trial had exposed the rather stark quality of the words used to 
describe the outcome of an interaction - drug "potentiated" or "inhibited" - 
and it had also been suggested that these words carried a somewhat strict 
pharmacological connotation, not ideally suited to a wide clinical setting. 
As these categories would be reserved for interactions of "clinical 
significance" on the final version of the Disc, the words "potentiated" 
and "inhibited" could well be re-appraised and replaced by terms which 
would be more clinically meaningful#
The concept of linking the smaller discs so that they would act as 
a single unit was an attractive one. It would, however, lead to some 
complications in construction and might eventually result in erroneous 
information if any disturbance in alignment occurred. But this idea 
did stress the importance of rapid identification of the position of 
the same "black" drug on each side of the large disc and moreover, 
emphasised that the Disc's acceptability would be enhanced by any measure 
which simplified its use#
The results of the Trial testified to the value of a drug interaction 
warning system, and, subject to the modifications discussed, confirmed 
that the Drug Disc would fulfil the necessary requirements#
C H A P T E R  7
FINAL DEVELOPMENT OF THE DRUG INTERACTION WARNING SYSTEM
,7. FINAL DEVELOPMENT OF THE DRUG INTERACTION WARNING SYSTEM
7.1. ADOPTION OF MODIFICATIONS
As the trial had produced such encouraging results, the Working 
Party had no hesitation in sanctioning further work on the project 
and recommended the formulation of a final version of the Disc with 
appropriate modifications.
The following were agreed on in principle;
1. Slight reduction in. diameter.
2. Linkage of the small discs.
3. Re-evaluation of all interactions and introduction of a 
"doubtful clinical significance" category, signified by a 
distinctive colour.
4* Improvement of the reference in the key to the results of 
an interaction.
5. No change in the symbol for "potentially serious interactions".
6. Substitution of some primary ("red") drugs with alternatives 
which were of greater clinical significance than those shown 
on the Trial Disc. This would also involve readjustment of 
drugs on the large disc.
7.2. RE-EVALUATION OF DRUG INTERACTIONS
All interactions were re-evaluated and assigned to one of three 
categories according to the following broad considerations;
1. CLINICALLY SIGNIFICANT INTERACTIONS
Interactions which were known to alter the pharmacological 
activity of one or both drugs in a combination, either enhancing 
or diminishing the therapeutic and/or toxic effects of the
drags concerned. Once recognised and understood, many 
such interactions could be allowed for by intelligent 
adjustment of dosage or dosing interval#
2. INTERACTIONS OF DOUBTFUL CLINICAL SIGNIFICANCE 
Interactions which had not, apparently, caused any significant 
harm in man. Many such interactions had been demonstrated 
in vitro or in animal experiments but seemed to have little 
relevance to the clinical situation.
3. POTENTIALLY SERIOUS INTERACTIONS
Interactions which were well documented as having harmful 
effects in man. This would serve to indicate that such 
combinations should be used with extreme caution, if at all#
7.3. FINAL VERSION OF THE DRUG INTERACTION WARNING SYSTEM
The final version, drafted by the present author and printed by 
Mr. P.S. V/aldie, is illustrated in Figures 64 and 65# It measured 
12.8 cm. in diameter and was constructed of thin but strong glossy 
cardboard. The smaller discs were linked at the centre and rotated 
together. The windows pointed in opposite directions when viewed from 
one side, (Figure 66) but when the disc was turned over in a horizontal 
direction (see arrows, Figure 66) the windows assumed identical positions 
and pointed at identical ("black”) drugs. This necessitated printing 
the "black” drugs clockwise on one side and anticlockwise on the other 
side, (Figure 67) so that the windows would "track" the same drug 
simultaneously.
Details of the large disc, shown in Figures 64 and 65 reveal that 
a considerable number of interactions were "down graded” to a new category 
of "doubtful clinical significance", indicated by a green colour.
Several changes in the "red” drugs were effected to highlight a number of
FIGURE 64 Draft of the final version of the 
Drug Disc : Side I, with detail
of the large disc.
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FIGURE 65 Draft of the final version of the 
Drug Disc : Side 2, with detail
of the large disc.
FIGURE 66 Details of the design of the final version of the 
Drug Disc, showing the relative position of the 
windows on each side.
Turned horizontally, as indicated by the arrows, 
the window and/or the peripheral drug at which 
it points, assume the same position.
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interactions which deserved this prominent position.' Thus, digoxin, 
iron, levodopa, and thiazide-type diuretics displaced allopurinol, 
antacids, corticosteroids and phenothiazines. Table 29 shows the final 
list of "red"'drugs. No significance was attached to the order in 
which these drugs appeared. It was dictated by the space available 
in the arcs, which diminished towards the centre of the small discs.
As can be seen in Figures 64 and 65 the words "potentiated" and 
"inhibited" were replaced by "effect enhanced" and "effect diminished", 
with a subscript reference to therapeutic and/or toxic effect, which 
carried a much more meaningful clinical connotation than "potentiated" 
and "inhibited".
Assignation of interactions to one of the three categories depended 
on the considerations already discussed, supported by opinions expressed 
by members of the Working Party and by doctors and pharmacists participating 
in the trial.
The importance of keeping an open mind on the category in which 
an interaction was placed must be stressed. It would be wrong to allow 
consideration of an interaction per se to obscure the other factors 
which determine the overall response of a patient to a drug or 
combination of drugs. Even when specific interactions can be predicted, 
the clinical consequences will be the result of the interplay of all 
these factors, as discussed in Chapter 3 of this thesis. The inclusion 
of interactions of "doubtful clinical significance" also underlines the 
impossibility of providing a complete and authoritative guide and stresses 
the need for regular review and revision of the system whenever necessary.
7.4. PRODUCTION AND WORLDWIDE DISTRIBUTION
Her Majesty's Stationery Office had been invited to participate in 
the project from the outset and had subsequently undertaken to print and
AMINOGLYCOSIDE ANTIBIOTICS
BETA ADRENERGIC BLOCKERS
THIAZIDE-TYPE DIURETICS
ORAL HYPOGLYCAEMICS
BARBITURATES
ALCOHOL
DIGOXIN
IRON
MONOAMINE OXIDASE INHIBITORS
TRICYCLIC ANTIDEPRESSANTS
COUMARIN ANTICOAGULANTS
ORAL CONTRACEPTIVES
ANTIHYPERTENSIVES
PHENYTOIN
ASPIRIN
LEVODOPA
TABLE 29 Final list of drugs shown on the small discs
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manufacture the Trial version of the Disc. It had been intended that
H.M.S.O. should thereafter maintain a continuing interest in the 
project and arrange for the printing, manufacture and distribution 
of the final version throughout the United Kingdom. Unfortunately, a 
number of problems, including a printers’ strike, precluded this, and 
alternative arrangements had to be made.
Many international pharmaceutical and advertising companies had 
offered to distribute the Disc throughout the world, but the 
professional and ethical considerations already presented obviated any 
direct association of this kind. However, an association with a 
reputable international publishing company specialising in medical 
literature had been recommended, and this encouraged further exploration 
of an approach made by the Excerpta Medica Foundation. This approach 
had initially taken the form of a request to obtain exclusive 
distribution rights for the Drug Disc in the United States and it was 
subsequently established that Excerpta Medica was prepared to promote 
the Drug Disc on a worldwide scale, not only in English, but also in 
Spanish, German, French, Italian, etc. A promotion plan drawn up by 
Excerpta Medica, based on private market research, indicated that other 
groups in addition to doctors and pharmacists, such as dentists, nurses 
and other paramedical health personnel had expressed interest in the 
Disc. The plan included distribution via third parties and it was 
suggested that the following organisations should be considered:
1. The World Medical Association and all national medical 
associations.
2. National and international specialist associations.
3. National and international pharmaceutical associations.
4* The international Hospital Federation and its national
affiliates.
5. National Ministries of Public Health and National Health
Services (e.g. the Department of Health and Social Security in
95
England and the Scottish Home and Health Department).
6. The World Health Organisation.
7* The International Red Gross Scoiety (i.R.C.S), national members in 
Western Countries and equivalents of the I.R.C.S. in the Middle 
East and Far East.
8. National and International Dental Associations.
If this pattern of dissemination was not feasible in certain areas, 
consideration should then be given to distribution via local pharmaceutical 
industries, provided that the Disc was not used as a vehicle for 
advertising material.
The plan also pointed out that there were approximately two million 
potential users of the Disc throughout the world, as detailed in Table 30, 
but no meaningful indication of the eventual response could be given.
An initial meeting with representatives from Excerpta Medica 
(Mr. James Cauverien, Director, and Mr. Jaap van Manen, then Deputy 
Director, now Director,) established that any agreement with the 
publishing company would include the supply of a large number of Discs 
free of charge to the Scottish Home and Health Department. This would
satisfy the principle aim of the Working Party - to effect a free
distribution of the Disc to all doctors working in the National Health 
Service.
Subsequent negotiations resulted in an agreement whereby Excerpta
Medica will produce and publish the Disc throughout the world under
licence for an initial period of ten years and will provide 60,000 
free copies for distribution throughout the National Health Service.
On completion of the agreement, the draft shown in Figures 64 and
65 was transferred to the .American division of Excerpta Medica. Its
format and content were scrutinised and approved by a number of American 
medical and pharmaceutical experts, but it was felt that the two smaller 
discs should be allowed to rotate independently. This would make the 
user responsible for alignment of the discs and would circumvent the
DOCTORS PHARMACISTS
Africa 52,000 14,000
Canada 35,000 11,500
U.S.A. 326,000 138,000
South America 140,000 23,000
Central America 48,000 2,700
Japan 125,000 65,000
Asia (excluding Communist 
China and the U.S.S.R.) 237,000 52,000
Europe 749,000 154,000
Australasia 20,000 1,000
Oceania 1,000 100
Total 1,733,000 461,300
TABLE 30 Geographical distribution of potential users of the
Drug Disc (compiled by Excerpta Medica from the W.H.O. 
Statistics Annual, 1970 (published 1974), extrapolated 
to 1974 on the basis of the increase in the number of 
doctors and pharmacists between I960 and 1970).
risk of faulty information arising from misalignment due to any 
mechanical failure in the linkage.
The final version produced by Excerpta Medica is shown in 
Figures 68 and 69. Each side is identified by the Roman numerals 
I and II, contained in an arrow, which serves to indicate the 
direction of the alphabetical order of the drugs on each side of the 
large disc. American spelling is used because this particular Disc 
is intended primarily for use in the U.S.A. Appropriate adjustments 
in spelling will be made for other English speaking countries such 
as Australia, New Zealand, South Africa and the United Kingdom. The 
latest example is presented with this thesis.
Each Disc will be accompanied by a guide to its use in the form 
of a small descriptive booklet, which will also indicate useful 
reference sources and the criteria which determined selection of the 
information presented on the Disc. Distribution within the United 
Kingdom, planned for early 1976, will be followed by worldwide 
distribution#
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CONCLUSIONS.
1. The increasing number of drugs prescribed for individual 
patients complicates modem therapeutics by presenting the opportunity 
for drug interactions to develop.
2. Drug interactions are one of the important factors which 
determine drug response in man. Unlike genetic and pathophysiological 
factors, which also make important contributions to this response, 
drug interactions are often the consequence of therapeutic decisions 
made by the doctor and sometimes by the patient. Many interactions, 
therefore, are avoidable.
3* An increased awareness of the problems associated with multiple
drug therapy is desirable and can be effected by the presentation of 
clinically relevant drug interaction information which should be 
available whenever therapy is prescribed.
4* A drug interaction warning system - the Drug Disc - has been
developed to provide this kind of information in as concise and 
convenient a form as possible.
5. A trial of the warning system in the United Kingdom and 
subsequent consumer research in other countries have confirmed the 
value of this system, both as a practical aid in prescribing and in 
teaching.
6. The degree of interest and enthusiasm stimulated by the Drug 
Disc reflects the problems implicit in modem multiple drug therapy 
and suggests that its worldwide distribution is warranted. It is 
hoped that it will contribute to safer, more rational prescribing.
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SUMMARY.
The history of drag therapy, from the earliest herial remedies to 
the impressive range of drugs available today, has proved the accuracy 
of the observation made by Sir William Osier in 18^1 that ”a desire to 
take medicine is, perhaps, the great feature which distinguishes man 
from other animals". Modem therapeutics has brought undoubted benefit 
to the patient, but not without risk. Unwanted effects and adverse 
reactions have now become an integral part of drug therapy. A small 
but significant proportion of these adverse reactions can be attributed 
to drug interactions, the phenomenon which occurs when the effects of 
one drug are modified by the prior or concurrent administration of 
another. Drugs may interact in ways not readily foreseeable from the 
action of either agent alone and may result in increased or reduced 
therapeutic efficacy, or sometimes toxic or even fatal reactions.
Numerous surveys have proved that in hospital medicine, muiuLple 
drag therapy is now common practice and such interactions as have come 
to light are merely a small indication of an ever increasing problem.
The number of over-the-counter drugs which can be purchased 
indiscriminately by the public complicates matters further because of 
the difficulty in ascertaining their composition and strength, the 
dosages employed, and the combinations in which they are taken with 
prescribed drugs. Alcohol consumption also adds to the therapeutic 
problems which face the doctor. If safe and effective therapy is to be 
attained, he must be aware of all the drugs that a patient is taking and 
carefully review all drug combinations.
Other factors may play an important part in determining the overall 
response of a patient to a drug, and drug interactions must be seen in 
this perspective. Genetic, environmental and pathophysiological factors, 
particularly renal and hepatic disease, together with allergy and 
idiosyncrasy may all make important contributions to this response.
In addition, variations in the biological availability of drugs due to 
pharmaceutical factors may assume importance. Assessment of the 
contribution of these various factors in individual patients is 
necessary for rational prescribing. Renal impairment, for example, 
reduces the clearance of drugs such as digoxin which depend on 
glomerular filtration for their excretion. Pharmacokinetic studies 
can derive mathematical models which define these changes accurately and 
predict appropriate dosage adjustments to maintain optimum therapeutic 
effect. Simulation of the changes can be usefully achieved by analogue 
computation.
A number of basic mechanisms are responsible for many drug 
interactions and an appreciation of these mechanisms can greatly 
facilitate their interpretation, prevention and treatment. Interactions 
can be viewed in terms of the three phases of drug action, the 
pharmaceutical phase, the pharmacokinetic phase and the pharmacodynamic 
phase.. Quantitative changes, reflected as alterations in plasma and 
tissue concentrations, occur during pharmaceutical and pharmacokinetic 
interactions while qualitative changes at receptor sites modifying onset, 
intensity or duration of action, or interference with homeostatic 
mechanisms occur as a result of interactions in the pharmacodynamic phase.
It is virtually impossible for the practising doctor to sustain the 
mass of detailed information which is now available on drug interactions. 
To overcome this problem, a simple, portable drug interaction warning 
system, the Drug Disc, has been developed. It consists of a reversible 
unit of two concentric superimposed discs which pivot freely about their 
common centre. Interactions are indicated by symbols which appear in a 
window cut into the upper disc when individual drugs or drug categories 
shown on the two discs are brought into alignment. The information 
presented embraces the majority of drug interactions which have a bearing 
on therapeutics and different symbols are used to grade interactions
3*
according to their degree of clinical significance. This grading 
was based on the nature and severity of the interaction, the adequacy 
of published information, and opinions expressed by the developers of 
the Disc, including a Working Party established by the Scottish Home and 
Health Department, and 450 doctors and pharmacists who participated in 
a trial of the Disc in the United Kingdom. This survey of attitudes 
about the warning system indicated that the majority of participants 
found the information provided to be both clinically useful and 
informative. Subsequent consumer research in other countries has 
confirmed that the system would be of value both as a practical aid in 
prescribing and in teaching. The degree of interest and enthusiasm 
stimulated by the Drug Disc showed that drug interactions are an aspect 
of modem medicine that cannot be ignored, and suggested that this kind 
of aid to prescribing was warranted. It is planned to effect a free 
distribution of the Disc to Health Service Doctors in the United Imgdom 
and the Excerpta Medica Foundation has accepted responsibility for its 
worldwide distribution*
Further experience with drug combinations and the introduction of 
new drugs will largely dictate much of the relevance of drug interactions 
in the future. The Drug Disc will be subjected to constant review and 
appropriate changes made whenever necessary. It is hoped that a system 
of this kind will foster a more critical approach to multiple drug therapy 
and help to reduce many of the hazards implicit in drug combinations.
